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Abstract
The natural products novobiocin and derrubone have both demonstrated Hsp90 inhibition and
structure–activity relationships have been established for each scaffold. Given these compounds
share several key structural features, we hypothesized that incorporation of elements from each could
provide insight to structural features important for Hsp90 inhibition. Thus, chimeric analogues of
novobiocin and derrubone were constructed and evaluated. These studies confirmed that the
functionality present at the 3-position of the isoflavone plays a critical role in determining Hsp90
inhibition and suggests that the bicyclic ring system present in both novobiocin and derrubone do
not share similar modes of binding.
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1. Introduction
In the past decade, the 90 kDa heat shock proteins (Hsp90) have garnered interest as a
therapeutic target for the treatment of several human pathologies, including cancer.1-6 As a
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molecular chaperone, Hsp90 is responsible for the conformational maturation and maintenance
of more than 100 cellular proteins.7,8 Hsp90 substrates function in a wide variety of cellular
processes, including receptors, transcription factors, and protein kinase signaling pathways.
9-14 Although many of these individual enzymes/proteins are individually sought-after
anticancer targets,15 inhibition of Hsp90 affords simultaneous degradation of multiple clients
through utilization of the ubiquitin-proteasome pathway.1,11,16-19 Consequently, inhibition of
the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic
pathways.16 In addition, studies have revealed that Hsp90 inhibitors accumulate in tumor cells
more effectively than normal tissue, leading to differential selectivities of >200 fold.20,21
Coupled with the observation that Hsp90 is overexpressed in a variety of human malignancies,
the development of Hsp90 inhibitors has become an attractive chemotherapeutic approach.
Novobiocin (1, Figure 1) is an ATP mimic that elicits antimicrobial activity through
competitive inhibition of DNA Gyrase B’s ATP-binding site. Neckers and co-workers
hypothesized that novobiocin may also be capable of binding Hsp90, which binds nucleotides
in a similar bent conformation as DNA Gyrase B. Subsequent studies demonstrated that
novobiocin binds to a novel site within the C-terminus of Hsp90,22-24 exhibits anti-tumor
activity (~700 μM, SkBr3 cells), and induces concentration-dependent degradation of Hsp90
client proteins.22 Several synthetic analogs of novobiocin have been prepared in an attempt to
improve upon the relatively-poor activity manifested by the natural product. One such
compound, A4, induced the expression of Hsp90 at 103−104 lower concentration than that
required for client protein degradation and exhibited potent neuroprotective effects, but
completely lacked anti-proliferative activity.25 In contrast, the A4-dimer displayed anti-
proliferative activity, implicating the benzamide side chain as a key moiety for conversion of
a non-toxic compound into an anti-cancer agent.26
In 2008, Burlison and co-workers described the first structure–activity relationships (SAR) for
monomeric novobiocin analogs that exhibit anti-proliferative activity.27 These studies
demonstrated the importance of the 3-benzamide functionality for exhibiting antitumor activity
and explored structural requirements of the benzamide sidechain. Further elucidation of the
anti-proliferative SAR for the novobiocin scaffold were provided by the construction of analogs
that contained variations of the coumarin ring system.28 Coumarins bearing substituents at the
5-, 6-, and 8-positions were found to possess positional and functional requirements that
attenuate anti-proliferative activity, while analogs with quinoline and naphthalene
functionalities suggested the coumarin lactone is not required. Together, these results supported
ongoing investigations aimed at identifying alternative ring systems to bridge the benzamide
and noviose moieties.
The prenylated isoflavone, derrubone (2, Figure 2), was originally isolated from Derris
robusta in 1969.29 In 2007, a high-throughput screen identified 2 as a low micromolar inhibitor
of Hsp90.30 Soon after, a library of derrubone analogues was prepared and evaluated for anti-
proliferation activity.31 Analogues exhibiting modest improvements in activity over the natural
product were identified and found to induce concentration-dependent degradation of Hsp90
client proteins. Preliminary structure–activity trends demonstrated the importance of the 6-
prenyl and 3-aryl sidechains for manifesting improved antiproliferative activity. However, no
further understanding was gained towards elucidating derrubone’s mode of Hsp90 inhibition,
either through interaction with the N-terminus, the C-terminus, or an alternative mechanism
of action.
Prior knowledge of SAR exhibited by novobiocin and derrubone analogues suggested these
two seemingly-diverse scaffolds may share common structural features (Figure 3). For
example, both molecules contain an electron-deficient core in the form of an isoflavone or
coumarin bicyclic ring system (highlighted in red) that are functionalized at the 3- and 7-
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positions with aryl-containing or hydroxyl functionalities, respectively. Furthermore,
novobiocin analogues with alternative bicyclic ring systems in lieu of the coumarin were shown
to retain Hsp90 inhibitory activity for novobiocin-derived C-terminal inhibitors.28 In addition,
previous studies on the novobiocin scaffold demonstrated that 6- and 8-alkyl groups were well-
tolerated and can afford increased antitumor activity (eg. 3).27,28,32 Similarly, 6- or 8-prenyl
groups also appear essential for derrubone analogues to exert anti-proliferative activity and
Hsp90 inhibition.31 These observations, along with the fact that no co-crystal structure of an
inhibitor bound to the Hsp90 C-terminus exists, led us to question whether these molecules
exert their activities through binding the same region of Hsp90. We hypothesized that the
bicyclic motif of 1 and 2 were analogous and that incorporation of elements from both
molecular libraries would provide insight into how structural features impact the mode and
capacity of Hsp90 inhibition. The design, synthesis and evaluation of such chimeric molecules
are described within this article.
2. Results and Discussion
2.1 Design of novobiocin-derrubone chimeras
To test our hypothesis, we set out to prepare a library of novobiocin and derrubone chimeric
analogues (Figure 4). This panel of analogues was unified by the isoflavone ring system that
would differentially impart functionalities common to either the novobiocin or derrubone
scaffold at the 3-, 5-, 6-, 7-, and 8-positions. In particular, key functionalities included the 3-
benzamide or 3-acetamide, 8-methyl, and 7-functionalities identified from previously-
described novobiocin libraries27,28,32 and the 3-(3,4-methylenedioxy)phenyl, 5-hydroxyl,
and 6-prenyl functionalities from the reported derrubone library.31 In addition, the panel
included a smaller subset of 2-amidoflavone analogues (5) to compare and contrast with the
corresponding 3-amido-isoflavones. Isoflavone analogues were grouped into two basic
structural categories; 3-amido-isoflavones (6) and 3-(3,4-methylenedioxy)phenyl-isoflavones
(7).
As shown in Scheme 1, the derivatives were prepared in modular fashion through sequential
coupling of noviose and acylation of the 3-amino-7-hydroxy-(iso)flavones (9). We envisioned
that the trichloroacetimidate of noviose carbonate (8) could be coupled with 3-amino-6-
hydroxyflavones or 3-amino-7-hydroxyisoflavones in a manner similar to that previously
described in our group.33 Selection of the biaryl acid and acetamide was based upon previously
obtained SAR for the benzamide side chain, which is known to bifurcate antitumor from
neuroprotective activity, respectively.25,27
2.2 Syntheses of 2-amido-flavone analogues
Novobiocin analogues that contain a flavone ring system in lieu of the coumarin were
constructed to assess the impact of alternative ring systems for Hsp90 inhibition. Benzyl
protection of the 5′-phenol of 11 provided 12 (Scheme 2).34 Reaction of 12 with N,N-
dimethylformamide dimethyl acetal afforded an enamine intermediate, which was condensed
with hydroxylamine–hydrochloride to give isoxazole, 13.35 Under thermal and basic
conditions, 13 was converted to the 3-aminoflavone, 14. Acylation of aniline 14 provided
amides 15a–b in excellent yield,36 which upon hydrogenolysis, yielded phenols 16a–b as
common intermediates.37 Acylation of the 7-hydroxyl functionality afforded 17a–b.36 Phenols
16a–b were reacted with the trichloroacetimide of noviose carbonate (8) in the presence of
boron trifluoride etherate to provide noviosylated intermediates that, after carbonate removal,
gave analogues 18a–b.33 Selective deprotection of the carbonate intermediates presented an
unexpected challenge as hydrolysis of the amide was also observed, likely a result of the
functionality’s vinylogous imide-like properties.
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2.3 Syntheses of 3-amido-isoflavone analogues
Similarly, 3-amido-isoflavone analogues were constructed as complementary, regioisomeric
variants of chromone-containing chimeric Hsp90 inhibitors. The two-step Hoesch
condensation of 20 with appropriate resorcinols or phloroglucinols (21) followed by imine
hydrolysis afforded aryl ketones 22a–c in high yield (Scheme 3).31,38 Notably, the phthalimide
functionality proved more useful than simply a nitrogen protecting group, as poor phthalide
solubility provided a handle to aid crystallization of subsequent intermediates. Cyclization of
intermediates 22a–c to isoflavones 23a–c was performed using Bischler–Napieralski
conditions as previously described.31 Interestingly, cyclization of phloroglucinol-containing
analogue 22c was accomplished in 48 h, while 4-keto-resorcinols 22a–b required 120 h.
Presumably, this difference resulted from hydrogen bonding interactions between the ortho-
phenol and ketone, precluding rotation to the required conformation for enamine displacement.
Phthalide deprotection of 23a–c under thermal and acidic conditions39,40 provided 3-amino-
isoflavone intermediates that were difficult to separate from the resulting ortho-phthalic acid.
Consequently, a one-pot, three-step deprotection, acylation, and hydrolysis procedure was
employed to convert 3-phthalamido intermediates 23a–c into 3-amido analogues 24a–f in
moderate yield. Acylation of intermediates 24a–f afforded 7-acetoxy analogues, 25a–f.36
Novioslyation and deprotection of 24a–f as previously described provided analogues 26a–f.33
2.4 Syntheses of 3-(3,4-methylenedioxy)phenyl-isoflavone analogues
Analogues based on the 3-aryl-isoflavone core of derrubone were constructed to determine
whether inclusion of 5-, 6-, 7-, and 8-functionalities of derrubone and/or novobiocin impart
increased Hsp90 inhibitory activitiy. Reaction of resorcinols 27a–b with (3,4-
methylenedioxyphenyl)acetonitrile under Hoesch conditions, followed by hydrolysis, afforded
2-keto-resorcinols 29a–b, which were cyclized to isoflavones 30a–b using the Bischler–
Napieralski protocol (Scheme 4).31,38,41 Together with 30c,31 these isoflavones served as
scaffolds for further analogue construction. Acylation of the 7-phenol in 30a–c afforded 31a–
c.36 Similarly, noviosylation of 30a–c and subsequent carbonate hydrolysis provided 7-
glycosylated analogues 32a–c.33
2.5 Syntheses of 5-deoxy-derrubone analogues
Starting with 5-deoxy-isoflavones 30a–b, allylation of the 7-phenol afforded 33a–b in
moderate yields (Scheme 5).36 Claisen rearrangement of 33a–b under thermal conditions
provided C-allyl analogues 34a–c.32 When 33a was reacted, formation of 8-allyl 34c was
preferred versus 6-allyl 34a as previously described, although both compounds could be
produced via this process.31 We hypothesized that inclusion of an 8-methyl functionality in
33b would serve a dual purpose in simultaneously providing the ~10-fold increased Hsp90
inhibitory activity demonstrated by 8-methylnovobiocin analogues27,28 and preventing
formation of the thermodynamically-preferred, yet ultimately undesired, 8-allyl Claisen
product. Protection of the phenols of 34a–34c as acetates yielded 7-acetoxy 35a–c,31 which
were subjected to olefin cross-metathesis with 2-methyl-2-butene using the second generation
Grubbs’ catalyst to afford prenylated compounds 36a–c.31 Removal of the acetate protecting
groups provided 5-deoxy derrubone analogs, 37a–c.31
2.6 Biological evaluation of flavone and isoflavone analogues
Upon construction of the novobiocin-derrubone chimeric library, the compounds were
evaluated for antiproliferative activity against SkBr3 (estrogen receptor negative, Her2
overexpressing breast cancer cells) and MCF-7 (estrogen receptor positive breast cancer cells).
As shown in Tables 1–2, all 2-acetamido-flavones and 3-acetamido-isoflavones (R3 = CH3)
were inactive, with the sole exception of 25e, which manifested modest anti-proliferative
activity (93.7 ± 6.5 μM) against MCF-7 cells. These results are unsurprising and support
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previous observations that A4 and other related 3-acetamidocoumarins do not affect cell
growth.25
In contrast, all but one biaryl benzamide-containing analogue (Tables 1–2, R3 = biaryl)
exhibited anti-proliferative activity ranging from ~3–50 μM against both cell lines. The 6-
hydroxyflavone, 16b, and 7-hydroxyisoflavones, 24b, 24d, and 24f, exhibited between 1.9–9-
fold decreased activity against SkBr3 cells. Analogous 7-acetoxy analogues 25b, 25d, and
25f did not demonstrate a large disparity in activities against MCF-7 and SkBr3 cells as their
phenolic counterparts. The sole exception to this trend was 17b, which was completely inactive
against both cell lines for reasons that remain unclear. By comparison, 7-noviosylated cogeners
(R5 = noviose) were less active than 7-hydroxy and 7-acetoxy analogues but demonstrated
equivalent potency against both cell lines. This observation supports the notion that 26b,
26d, and 26f induce their activity through similar modes of action against both MCF-7 and
SkBr3 cells, a feature typically observed for other novobiocin-derived Hsp90 inhibitors.27,28,
32
Unfortunately, in comparison to previously-described coumarin-containing analogues27, both
the 2-amidoflavone and 3-amidoisoflavone ring systems demonstrated decreased anti-
proliferative activity. In comparison to the analogous 8-methylcoumarin-containing analogue,
18b, 25f, and 26d manifested between 0–6-fold decreased activities against MCF-7 and SkBr3
cell lines. Interestingly, most analogues containing the 5-hydroxyl exhibited similar activities
as analogous 5-proteo derivatives, suggesting that this functionality neither increases nor
decreases activity. In contrast to trends observed in coumarin-containing analogues,27,28
inclusion of the 8-methyl functionality to the isoflavone derivatives garnered a more modest
1.8–2.0-fold increase in antiproliferative activity for 7-hydroxy and 7-acetoxy derivatives and
a 1.6–2.0-fold decrease in activity for 7-noviosylated products.
As shown in Table 3, 3-(3,4-methylenedioxy)phenyl-isoflavone analogues with similarity to
the derrubone scaffold demonstrated interesting trends in antiproliferation activity. In contrast
to 3-amido analogues, those lacking either 7-noviose or prenyl functionalities were inactive
against both cell lines, an observation supportive of previously-described trends.31 Detectable
antiproliferation activity was only observed for analogues bearing either a 7-noviose, 6-prenyl,
or 8-prenyl functionality. The 7-noviosylated analogues 32a–b manifested IC50s between 9-21
μM. For reasons that remain unclear, 32c was completely inactive. In contrast, prenylated
derivatives, 37a–c, exhibited activities ranging from 13 μM to greater than 100 μM.
Replacement of 7-noviose (32a) with either a 6- (37a) or 8-prenyl (37c) functionality appeared
to induce differential properties against these two cell lines.
Comparing the antiproliferation activities of 37a–c to those observed for 2 and other
previously-disclosed derrubone analogues31 provides insight into the role of the 5-hydroxyl
and 8-methyl functionalities. While the data suggests that removal of the 5-hydroxyl
functionality does not impact anti-proliferation activity, its inclusion is useful for selectively
installing the 6-prenyl functionality in derrubone analogues.31 We had hoped that inclusion of
an 8-methyl (37b) would simultaneously provide enhanced activity and selectivity during the
Claisen rearrangement. While incorporation of an 8-methyl fulfilled the latter objective, such
analogues demonstrated nearly 4-fold decreased activity.
Some of the more intriguing structure–activity trends were observed through comparison of
3-biarylbenzamide isoflavone analogues and 3-(3,4-methylenedioxy)phenyl isoflavone
derivatives. The 7-hydroxy and 7-acetoxy isoflavone analogues with the 3-biaryl amide were
collectively the most potent compounds in the library, while corresponding analogues
containing the 3-(3,4-methylenedioxy)phenyl sidechain were inactive. On its own, this
observation implicates the essential nature of the 3-benzamide sidechain for manifestation of
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anti-proliferation activity. However, the same trend was not evident when comparing the 7-
noviosylated derivatives, as 3-(3,4-methyelendioxy)phenyl-containing analogues 32a–b were
between 1.6–2.8-fold more active than 3-benzamide analogues 26b and 26d. Together, these
trends indicate that the relationship between inclusion of the 3-functionality and
antiproliferation activity is complex.
To provide additional support that the anti-proliferation activities of this library of analogues
results from Hsp90 inhibition, analogues 26b and 37c were evaluated for their ability to induce
degradation of Hsp90-dependent client proteins. As shown in Figure 5, analogues 26b and
37c both induced concentration-dependent degradation of Hsp90 client proteins Her2 and cRaf.
β-Actin, a non-Hsp90-dependent protein, was not affected by these analogues indicating
selective degradation of Hsp90-dependent clients. The antiproliferative activities (26b, IC50 =
25.2 μM; 37c, IC50 = 39.1 μM) correlate well with the concentrations needed to induce Hsp90
client protein degradation, thereby linking Hsp90 inhibition directly to cell viability. None of
these analogues induce the concentration-dependent increase in Hsp90 levels correlating to
activation of the heat shock response, a feature consistent with other C-terminal Hsp90
inhibitors. A summary of structure–activity trends for flavone and isoflavone chimeras of
novobiocin and derrubone are depicted in Figure 6.
3. Conclusions
Although many of the chimeric analogues of novobiocin and derrubone exhibit
antiproliferative activities, differences observed in structure–activity trends do not support our
original hypothesis that the isoflavone ring of derrubone is analogous to the coumarin ring
system present in the novobiocin scaffold. However, the identity of the functionality at the 3-
position appears to play a critical role in determining the potency and mode of antiproliferative
activity observed for both scaffolds. The 3-acetamide analogues were found to be non-toxic
and may represent scaffolds that exhibit neuroprotection activity similar to A4, while 3-
biarylbenzamide derivatives (eg. 26b) display moderate antiproliferation and downregulation
of Hsp90 client proteins. Biarylbenzamide analogues containing a hydroxyl (16b) or acetoxy
(25d) substituent in lieu of the typical noviose sugar exert antiproliferative effects more readily
than the corresponding noviosylated derivatives. Isoflavone analogues containing the 3-aryl




Potassium carbonate (1.81 g, 13.09 mmol) and benzyl bromide (1.56 mL, 2.24 g, 13.12 mmol)
were added in sequence to 2′,5′-dihydroxyacetophenone (2.00 g, 13.15 mmol) in acetone (41.0
mL) and the solution was then then heated to reflux for 48 h. After cooling to rt, the reaction
was diluted with saturated aqueous NaHCO3 solution (50 mL) and extracted with EtOAc (3 ×
250 mL). The combined organic layers were washed with saturated aqueous NaCl solution
(500 mL), dried (Na2SO4), filtered, and concentrated. The residue was purified via column
chromatography (SiO2, 5:1 Hexanes:EtOAc) to give 12 as a yellow amorphous solid (2.92 g,
92%): 1H NMR (CDCl3, 500 MHz) δ 11.87 (s, 1H), 7.47-7.38 (m, 4H), 7.30 (m, 1H), 7.26 (d,
J = 3.0 Hz, 1H), 7.19 (dd, J = 9.1, 3.0 Hz, 1H), 6.93 (d, J = 9.1 Hz, 1H), 5.06 (s, 2H), 2.59 (s,
3H).
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A suspension of 12 (5.05 g, 20.82 mmol) in N,N-dimethylformamide dimethyl acetal (40.8
mL) was then heated to 90° C for 2 h. After cooling to rt, the yellow precipitate was collected
by filtration, washed with cold hexanes, and used without further purification.
Hydroxylamine hydrochloride (1.76 g, 25.29 mmol) was added to a solution of the enamine
(20.82 mmol) in EtOH (245 mL) and the solution was then heated to reflux for 1 h. After
cooling to rt, the solvent was concentrated, the residue was washed with water (200 mL), the
solid was collected by filtration, redissolved in hot EtOAc (400 mL), filtered, and concentrated.
Recrystallization from EtOAc:Hexanes gave 13 as a near-colorless amorphous solid (4.00 g,
72% over two steps): 1H NMR (DMSO-d6, 500 MHz) δ 10.17 (brs, 1H), 8.62 (d, J = 1.8 Hz,
1H), 7.47 (m, 2H), 7.43-7.37 (m, 3H), 7.33 (m, 1H), 7.03 (dd, J = 8.9, 3.0 Hz, 1H), 6.97 (d,
J = 8.9 Hz, 1H), 6.89 (d, J = 1.8 Hz, 1H), 5.11 (s, 2H); 13C NMR (DMSO-d6, 500 MHz) δ
164.9, 151.6, 151.1, 148.9, 137.2, 128.4 (2C), 127.8, 127.6 (2C), 118.9, 117.5, 113.8, 111.7,
102.6, 69.8; IR (film) νmax 3101, 1576, 1518, 1479, 1421, 1381, 1273, 1258, 1204, 1124, 1020,
930, 816, 789, 7466, 698 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C16H13NO3, 268.0974;
found, 268.0967.
5.3 2-Amino-6-(benzyloxy)-4H-chromen-4-one (14)
Triethylamine (2.30 mL, 1.67 g, 16.50 mmol) was added to 13 (2.24 g, 8.38 mmol) in anhydrous
N,N-dimethylformamide (93.0 mL) and the solution was then heated to 140–150° C for 18 h.
After cooling to rt, the solvent was concentrated, the residue was suspended in water (200 mL),
and the resulting solid was collected by filtration through celite. The solid was eluted with hot
MeOH, the solvent was concentrated, cold Et2O (100 mL) was added, and the solid collected
by filtration to give 14 as a yellow-orange amorphous solid (2.20 g, 57%): 1H NMR (DMSO-
d6, 500 MHz) δ 7.49-7.44 (m, 4H), 7.43 (d, J = 3.1 Hz, 1H), 7.41 (m, 2H), 7.34 (m, 1H), 7.33
(d, J = 9.0 Hz, 1H), 7.25 (dd, J = 9.0, 3.1 Hz, 1H), 5.17 (s, 2H), 5.16 (s, 1H); 13C NMR (DMSO-
d6, 500 MHz) δ 174.2, 164.8, 154.9, 147.7, 136.9, 128.4 (2C), 127.9, 127.7 (2C), 123.7, 120.6,
117.9, 107.1, 84.8, 69.6; IR (film) νmax 1609, 1556, 1541, 1456, 1275, 1261, 764, 750, 681
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C16H13NO3, 268.0974; found, 268.0985.
5.4 N-(6-(Benzyloxy)-4-oxo-4H-chromen-2-yl)acetamide (15a)
4-(Dimethylamino)pyridine (346 mg, 2.83 mmol) was added to a suspension of 14 (490 mg,
1.83 mmol) in anhydrous acetonitrile (13.0 mL) at rt. After 3 h, acetyl chloride (675 μL, 745
mg, 9.49 mmol) was added and the solution was then heated to reflux for 18 h. After cooling
to rt, water (100 mL) was added and the precipitate was collected by filtration and washed with
cold Et2O (100 mL) to give 15a as a colorless amorphous solid (495 mg, 87%): 1H NMR
(DMSO-d6, 500 MHz) δ 11.24 (brs, 1H), 7.50 (d, J = 9.1 Hz, 1H), 7.50-7.46 (m, 3H), 7.45-7.39
(m, 3H), 7.35 (m, 1H), 6.77 (s, 1H), 5.22 (s, 2H), 2.15 (s, 3H); 13C NMR (DMSO-d6, 500
MHz) δ 176.7, 169.2, 156.6, 155.5, 147.9, 136.6, 128.5 (2C), 128.0, 127.7 (2C), 123.6, 123.0,
119.0, 106.5, 95.0, 69.8, 24.2; IR (film) νmax 2920, 2851, 1711, 1622, 1603, 1564, 1458, 1261,




4-(Dimethylamino)pyridine (346 mg, 2.83 mmol) was added to a suspension of 14 (500 mg,
1.87 mmol) in anhydrous acetonitrile (10.0 mL) at rt. After 3 h, freshly prepared 4-methoxy-3-
(3-methoxyphenyl)benzoyl chloride28 (1.02 g, 3.67 mmol) in anhydrous acetonitrile (3.0 mL)
was added and the solution was then heated to reflux for 18 h. After cooling to rt, water (100
mL) was added, the precipitate was collected by filtration and washed with cold Et2O (200
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mL). The solid was redissolved in EtOAc (400 mL) and was washed with 1M aqueous NaOH
solution (2 × 200 mL), saturated aqueous NaHCO3 solution (200 mL), saturated aqueous NaCl
solution (200 mL), dried (Na2SO4), filtered, and concentrated to give 15b as a light brown
amorphous solid (658 mg, 69%): 1H NMR (DMSO-d6, 500 MHz) δ 11.42 (brs, 1H), 8.05 (dd,
J = 8.5, 2.5 Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.52-7.48 (m, 3H), 7.44
(dd, J = 9.2, 3.1 Hz, 1H), 7.42 (m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.36 (m, 1H), 7.28 (d, J = 8.6
Hz, 1H), 7.17-7.13 (m, 2H), 6.97 (m, 1H), 6.96 (s, 1H), 5.23 (s, 2H), 3.81 (s, 3H); 13C NMR
(DMSO-d6, 125 MHz) δ 176.8, 173.4, 165.0, 159.6, 159.0, 155.5, 148.2, 138.5, 136.7, 130.0,
129.2, 129.1, 128.5 (2C), 128.0, 127.8 (2C), 125.1, 123.7, 123.0, 121.8, 119.1, 115.4, 112.5,
111.6, 106.5, 96.3, 69.8, 56.0, 55.1; IR (film) νmax 1686, 1601, 1572, 1528, 1502, 1479, 1452,
1285, 1231, 1204, 1190, 1034, 1020, 818, 783, 754, 733, 700 cm−1; HRMS (ESI+) m/z: [M +
H]+ calcd for C31H25NO6, 508.1760; found, 508.1745.
5.6 N-(6-Hydroxy-4-oxo-4H-chromen-2-yl)acetamide (16a)
Palladium on carbon (10%, 48 mg) was added to 15a (85 mg, 0.28 mmol) in 1:1 EtOAc:EtOH
(17 mL) and the reaction was placed under an atmosphere of H2 and stirred for 48 h at rt. The
reaction was filtered through celite and the solvent was concentrated. Recrystallization from
CH2Cl2:Et2O gave 16a as a near-colorless amorphous solid (37 mg, 61%): 1H NMR (DMSO-
d6, 500 MHz) δ 11.19 (brs, 1H), 9.95 (brs, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.26 (d, J = 3.0 Hz,
1H), 7.17 (dd, J = 8.9, 3.0 Hz, 1H), 6.72 (s, 1H), 2.13 (s, 3H); 13C NMR (DMSO-d6, 500 MHz)
δ 177.0, 169.3, 154.7, 146.8, 123.8, 122.2, 118.6, 108.0, 107.2, 94.9, 24.3; IR (film) νmax 1676,
1585, 1263, 1227, 814, 741 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C11H9NO4, 220.0610;
found, 220.0616.
5.7 N-(6-Hydroxy-4-oxo-4H-chromen-2-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (16b)
Palladium on carbon (10%, 531 mg) was added to 15b (499 mg, 0.98 mmol) in 3:1
EtOAc:EtOH (120 mL) and the reaction was placed under an atmosphere of H2 and stirred for
18 h at rt. The reaction was filtered through celite and the solvent was concentrated.
Recrystallization from CH2Cl2:Et2O gave 16b as an orange amorphous solid (282 mg,
69%): 1H NMR (DMSO-d6, 500 MHz) δ 11.35 (brs, 1H), 9.96 (brs, 1H), 8.04 (dd, J = 8.5, 2.4
Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.30 (d,
J = 3.0 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.20 (dd, J = 8.9, 3.0 Hz, 1H), 7.17-7.13 (m, 2H),
6.97 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 6.91 (s, 1H), 3.88 (s, 3H), 3.81 (s, 3H); 13C NMR (DMSO-
d6, 125 MHz) δ 177.0, 159.6, 159.0, 159.0, 157.3, 154.7, 147.1, 138.5, 130.6, 130.0, 129.2,
129.1, 125.2, 123.8, 122.3, 121.8, 118.7, 115.4, 112.5, 111.6, 108.0, 96.2, 56.0, 55.1; IR (film)
νmax 1684, 1603, 1576, 1522, 1506, 1474, 1229, 1206, 681, 650 cm−1; HRMS (ESI+) m/z: [M
+ Na]+ calcd for C24H19NO6, 440.1110; found, 440.1098.
5.8 2-Acetamido-4-oxo-4H-chromen-6-yl acetate (17a)
4-(Dimethylamino)pyridine (28 mg, 0.23 mmol) and acetyl chloride (32 μL, 35 mg, 0.45 mmol)
were sequentially added to 16a (31 mg, 0.14 mmol) in anhydrous acetonitrile (1.00 mL) and
the solution was then heated to 80° C in a sealed flask for 18 h. After cooling to rt, the reaction
was diluted with water (10 mL) and the solid was collected by filtration and washed with cold
Et2O (20 mL) to give 17a as a light brown amorphous solid (27 mg, 74%): 1H NMR (DMSO-
d6, 500 MHz) δ 11.34 (brs, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.60 (d, J = 8.9 Hz, 1H), 7.55 (dd,
J = 8.9, 2.8 Hz, 1H), 6.81 (s, 1H), 2.31 (s, 3H), 2.16 (s, 3H); 13C NMR (DMSO-d6, 500 MHz)
δ 176.5, 169.4, 169.3, 157.0, 150.8, 147.4, 127.9, 123.6, 119.0, 117.2, 95.1, 24.3, 20.9; IR
(film) νmax 1759, 1747, 1713, 1693, 1607, 1205, 1190, 1170, 1128, 986, 939, 899, 841, 820,
804, 750, 725, 685 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C13H11NO5, 262.0715; found,
262.0717.
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5.9 2-(4-Methoxy-3-(3-methoxyphenyl)benzamido)-4-oxo-4H-chromen-6-yl acetate (17b)
4-(Dimethylamino)pyridine (33 mg, 0.27 mmol) and acetyl chloride (44 μL, 49 mg, 0.62 mmol)
were sequentially added to 16b (27 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL) and the
solution was then heated to 80° C in a sealed flask for 18 h. After cooling to rt, the reaction
was diluted with water (5 mL) and the solid was collected by filtration and washed with cold
Et2O (10 mL) to give 17b as a brown amorphous solid (18 mg, 61%): 1H NMR (DMSO-d6,
500 MHz) δ 11.50 (brs, 1H), 8.06 (dd, J = 8.4, 2.4 Hz, 1H), 8.04 (m, 1H), 7.73 (d, J = 2.8 Hz,
1H), 7.64 (d, J = 9.0 Hz, 1H), 7.57 (dd, J = 9.0, 2.8 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.29 (d,
J = 8.6 Hz, 1H), 7.18-7.14 (m, 2H), 7.00 (s, 1H), 6.97 (ddd, J = 8.2, 2.5, 0.7 Hz, 1H), 3.89 (s,
3H), 3.81 (s, 3H), 2.32 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 176.5, 169.3, 165.1, 159.7,
159.0, 157.7, 151.1, 147.4, 138.5, 130.7, 130.1, 129.3, 129.1, 128.0, 125.0, 123.6, 121.8, 119.0,
117.2, 115.4, 112.5, 111.7, 96.3, 56.0, 55.1, 20.9; IR (film) νmax 1749, 1686, 1614, 1605, 1576,
1539, 1520, 1508, 1474, 1456, 1369, 1288, 1275, 1232, 1205, 1190, 1175, 1018, 818, 719
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C26H21NO7, 460.1396; found, 460.1384.
5.10 N-(6-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-4-oxo-4H-chromen-2-yl)acetamide (18a)
Boron trifluoride etherate (15 μL, 0.12 mmol) was added to 16a (49 mg, 0.23 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (167 mg, 0.46 mmol) in anhydrous CH2Cl2 (7.70 mL).
After stirring at rt for 18 h, triethylamine (30 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL) and triethylamine (72 μL) and stirred for 8 h at rt.
The solvent was concentrated and the residue purified via PTLC (SiO2, 8:1 CH2Cl2:MeOH)
to give 18a as a colorless amorphous solid (4 mg, 5% over two steps): 1H NMR (DMSO-d6,
400 MHz) δ 7.61 (dd, J = 2.1, 1.1 Hz, 1H), 7.25-7.24 (m, 2H), 6.90 (s, 1H), 5.48 (d, J = 2.3
Hz, 1H), 4.05 (dd, J = 9.2, 3.4 Hz, 1H), 3.98 (dd, J = 3.3, 2.4 Hz, 1H), 3.51 (s, 3H), 3.25 (d,
J = 9.4 Hz, 1H), 2.11 (s, 3H), 1.26 (s, 3H), 1.06 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ
179.6, 169.4, 156.9, 154.1, 148.9, 123.8, 123.2, 118.5, 109.9, 98.6, 96.3, 84.2, 78.5, 71.0, 68.4,
61.7, 28.5, 24.0, 22.9; IR (film) νmax 3423, 1722, 1624, 1601, 1583, 1504, 1483, 1458, 1408,
1364, 1273, 1227, 1115, 1032, 991, 748 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C19H23NO8, 394.1502; found, 394.1497.
5.11 N-(6-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-4-oxo-4H-chromen-2-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (18b)
Boron trifluoride etherate (60 μL, 0.49 mmol) was added to 16b (101 mg, 0.24 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (178 mg, 0.49 mmol) in anhydrous CH2Cl2 (8.20 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL) and triethylamine (200 μL) and
stirred for 6 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2, 2
× 6:2:1 CH2Cl2:EtOAc:MeOH) to give 18b as a colorless amorphous solid (10 mg, 7% over
two steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 7.93 (dd, J = 8.6, 2.4 Hz, 1H), 7.86 (d, J =
2.4 Hz, 1H), 7.64 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.30-7.26 (m, 2H), 7.10 (s, 1H),
7.09 (m, 1H), 7.06 (dd, J = 2.5, 1.6 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 6.90 (ddd, J = 8.2, 2.5,
0.9 Hz, 1H), 5.53 (d, J = 2.4 Hz, 1H), 4.12 (dd, J = 9.0, 3.5 Hz, 1H), 4.07 (m, 1H), 3.87 (s,
3H), 3.83 (s, 3H), 3.57 (s, 3H), 3.30 (d, J = 9.1 Hz, 1H), 1.33 (s, 3H), 1.12 (s, 3H); 13C NMR
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(CDCl3/MeOD, 125 MHz) δ 179.3, 164.7, 160.4, 159.4, 157.0, 154.2, 149.1, 138.7, 130.9,
130.6, 129.4, 129.3, 125.2, 124.0, 123.2, 122.1, 118.5, 115.5, 113.1, 111.2, 110.1, 98.5, 96.9,
84.3, 78.6, 71.0, 68.5, 61.9, 56.0, 55.5, 28.7, 23.1; IR (film) νmax 3483, 2976, 2935, 2837, 1691,
1609, 1578, 1524, 1481, 1460, 1367, 1304, 1275, 1234, 1205, 1184, 1157, 1132, 1113, 1078,
1051, 1024, 995, 968, 829, 760, 737 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C32H33NO20, 592.2183; found, 592.2161.
5.12 2-(1,3-Dioxoisoindolin-2-yl)acetonitrile (20)
Aminoacetonitrile hydrochloride (5.00 g, 54.06 mmol), triethylamine (7.50 mL, 5.45 g, 53.81
mmol), and phthalic anhydride (8.00 g, 54.02 mmol) in chloroform (65 mL) were then heated
to reflux for 18 h. After cooling to rt, the reaction was poured into water (65 mL) and the
organic layer was washed with water (100 mL), saturated aqueous NaCl solution (100 mL),
dried (Na2SO4), filtered, and concentrated to give 20 as a colorless amorphous solid (7.54 g,
75%): 1H NMR (CDCl3, 500 MHz) δ 7.94 (m, 2H), 7.81 (m, 2H), 4.59 (s, 2H).
5.13 1-(2,4-Dihydroxyphenyl)-2-(2-isoindoline-1,3-dione)ethanone (22a)
Resorcinol (5.66 g, 51.44 mmol) and 20 (8.01 g, 43.02 mmol) in EtOAc (125 mL) was cooled
to 0° C. After 15 min, zinc chloride (3.91 g, 28.72 mmol) was added, hydrochloric acid was
bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed to rt
over 18 h. The reaction was filtered and the resulting solid was washed with cold EtOAc (3 ×
100 mL) then added to water (70 mL) and then heated to reflux for 3 h. After cooling to rt, the
solid was collected by filtration and washed with water (3 × 100 mL), then Et2O (3 × 150 mL)
to give 22a as a colorless amorphous solid (9.91 g, 78%): 1H NMR (DMSO-d6, 500 MHz) δ
11.41 (brs, 1H), 10.68 (brs, 1H), 7.95 (m, 2H), 7.91 (m, 2H), 7.82 (d, J = 8.8 Hz, 1H), 6.42
(dd, J = 8.8, 2.3 Hz, 1H), 6.38 (d, J = 2.3 Hz, 1H), 5.06 (s, 2H); 13C NMR (DMSO-d6, 500
MHz) δ 192.5, 167.7 (2C), 165.0, 162.8, 134.8 (2C), 132.5, 131.6 (2C), 123.4 (2C), 112.1,
108.7, 102.5, 45.5; IR (film) νmax 1776, 1693, 1682, 1643, 1420, 1366, 1352, 1313, 1219, 1194,
1182, 1105, 935, 845, 795, 756, 719, 606, 548 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C16H11NO5, 298.0715; found, 298.0709.
5.14 1-(2,4-Dihydroxy-3-methylphenyl)-2-(2-isoindoline-1,3-dione)ethanone (22b)
2-Methylresorcinol (2.38 g, 19.15 mmol) and 20 (3.00 g, 16.12 mmol) in EtOAc (60 mL) was
cooled to 0° C. After 15 min, zinc chloride (1.49 g, 10.95 mmol) was added, hydrochloric acid
was bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed
to rt over 18 h. The reaction was filtered and the resulting solid was washed with cold EtOAc
(3 × 50 mL) then added to water (25 mL) and then heated to reflux for 3 h. After cooling to rt,
the solid was collected by filtration and washed with water (3 × 50 mL), then Et2O (3 × 100
mL) to give 22b as a yellow amorphous solid (3.39 g, 68%): 1H NMR (DMSO-d6, 500 MHz)
δ 12.09 (brs, 1H), 10.81 (brs, 1H), 7.97 (m, 2H), 7.92 (m, 2H), 7.86 (d, J = 8.9 Hz, 1H), 6.56
(d, J = 8.9 Hz, 1H), 5.18 (s, 2H), 1.98 (s, 3H); 13C NMR (DMSO-d6, 500 MHz) δ 195.4, 167.6
(2C), 163.3, 162.0, 134.8 (2C), 131.5 (2C), 129.3, 123.4 (2C), 110.5, 110.1, 107.8, 43.2, 7.6;
IR (film) νmax 3398, 1767, 1705, 1630, 1618, 1421, 1393, 1317, 1259, 1101, 1067, 955, 783,
764, 752, 716 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C17H13NO5, 312.0872; found,
312.0859.
5.15 1-(2,4,6-Trihydroxyphenyl)-2-(2-isoindoline-1,3-dione)ethanone (22c)
Phloroglucinol (4.07 g, 32.29 mmol) and 20 (5.00 g, 26.86 mmol) in 1:1 Et2O:EtOAc (100
mL) was cooled to 0° C. After 15 min, zinc chloride (2.42 g, 17.78 mmol) was added,
hydrochloric acid was bubbled through the solution for 10 min, and the reaction vessel was
sealed and warmed to rt over 18 h. The reaction was filtered and the resulting solid was washed
with cold EtOAc (3 × 50 mL) then added to water (150 mL) and then heated to reflux for 3 h.
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After cooling to rt, the solid was collected by filtration and washed with water (3 × 100 mL),
then Et2O (3 × 150 mL) to give 22c as a yellow amorphous solid (5.25 g, 62%): 1H NMR
(DMSO-d6, 500 MHz) δ 12.07 (brs, 2H), 10.68 (brs, 1H), 7.95 (m, 2H), 7.90 (m, 2H), 5.89 (s,
2H), 4.98 (s, 2H); 13C NMR (DMSO-d6, 500 MHz) δ 195.1, 167.7 (2C), 166.0, 164.3 (2C),
134.8 (2C), 131.6 (2C), 123.3 (2C), 102.2, 94.8 (2C), 47.2; IR (film) νmax 3234, 1761, 1693,
1634, 1587, 1454, 1393, 1229, 1161, 1111, 1068, 951, 712, 513 cm−1; HRMS (ESI+) m/z: [M
+ H]+ calcd for C16H11NO6, 314.0665; found, 314.0679.
5.16 2-(7-Hydroxy-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23a)
Boron trifluoride etherate (3.54 mL, 28.68 mmol) was added to 22a (1.32 g, 4.43 mmol) in
anhydrous N,N-dimethylformamide (17.4 mL) at rt. After 10 min, methanesulfonyl chloride
(1.44 mL, 2.13 g, 18.60 mmol) was added and the reaction was then heated to 90° C for 5 d.
After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration.
The solid was dissolved in EtOAc/MeOH (600 mL) and the organic layers were washed with
water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO4/NaSO4), filtered,
and concentrated to give 23a as a brown amorphous solid (824 mg, 79%): 1H NMR (DMSO-
d6, 500 MHz) δ 11.14 (brs, 1H), 8.67 (s, 1H), 8.03 (m, 2H), 7.97 (m, 2H), 7.95 (d, J = 8.8 Hz,
1H), 7.03 (dd, J = 8.8, 2.2 Hz, 1H), 7.01 (d, J = 2.2 Hz, 1H); 13C NMR (DMSO-d6, 500 MHz)
δ 171.7, 166.7 (2C), 163.5, 157.7, 157.0, 135.2 (2C), 131.4 (2C), 127.1, 123.8 (2C), 117.4,
116.1, 115.9, 102.8; IR (film) νmax 2924, 2856, 1722, 1607, 1593, 1375, 1290, 1105, 764, 748,
717 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C17H9NO5, 308.0559; found, 308.0571.
5.17 2-(7-Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23b)
Boron trifluoride etherate (5.00 mL, 40.51 mmol) was added to 22b (2.00 g, 6.43 mmol) in
anhydrous N,N-dimethylformamide (24.8 mL) at rt. After 10 min, methanesulfonyl chloride
(2.06 mL, 3.05 g, 26.62 mmol) was added and the reaction was then heated to 90° C for 5 d.
After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration.
The solid was dissolved in EtOAc/MeOH (600 mL) and the organic layers were washed with
water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO4/NaSO4), filtered,
and concentrated to give 23b as a reddish-brown amorphous solid (1.72 g, 83%): 1H NMR
(DMSO-d6, 500 MHz) δ 11.05 (brs, 1H), 8.73 (s, 1H), 8.04 (m, 2H), 7.97 (m, 2H), 7.82 (d, J
= 8.7 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 2.28 (s, 3H); 13C NMR (DMSO-d6, 500 MHz) δ 172.1,
166.8 (2C), 161.0, 157.0, 155.8, 135.2 (2C), 131.5 (2C), 123.8 (2C), 123.6, 117.1, 116.0, 114.8,
111.8, 8.1; IR (film) νmax 3393, 1728, 1717, 1661, 1645, 1614, 1385, 1275, 1259, 750 cm−1;
HRMS (ESI+) m/z: [M + H]+ calcd for C18H11NO5, 322.0715; found, 322.0721.
5.18 2-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23c)
Boron trifluoride etherate (10.8 mL, 87.51 mmol) was added to 22c (4.01 g, 12.81 mmol) in
anhydrous N,N-dimethylformamide (53.2 mL) at rt. After 10 min, methanesulfonyl chloride
(4.40 mL, 6.51 g, 56.85 mmol) was added and the reaction was then heated to 90° C for 2 d.
After cooling to rt, water (600 mL) was added, the resulting solid was collected by filtration.
The solid was dissolved in EtOAc/MeOH (800 mL) and the organic layers were washed with
water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO4/NaSO4), filtered,
and concentrated to give 23c as a reddish-brown amorphous solid (4.12 g, 99%): 1H NMR
(DMSO-d6, 500 MHz) δ 11.97 (brs, 1H), 11.24 (brs, 1H), 8.69 (s, 1H), 8.04 (m, 2H), 7.98 (m,
2H), 6.54 (d, J = 2.1 Hz, 1H), 6.34 (d, J = 2.1 Hz, 1H); 13C NMR (DMSO-d6, 500 MHz) δ
176.5, 166.6 (2C), 165.2, 161.3, 158.1, 157.6, 135.3 (2C), 131.3 (2C), 123.9 (2C), 115.8, 104.1,
99.9, 94.8; IR (film) νmax 1717, 1699, 1385, 1362, 1175, 1150, 1101, 1041, 679, 650 cm−1;
HRMS (ESI+) m/z: [M + H]+ calcd for C17H9NO6, 324.0508; found, 324.0514.
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Compound 23a (192 mg, 0.62 mmol) in glacial acetic acid (2.0 mL) and concentrated
hydrochloric acid (2.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with
water (10 mL) and the solvent was concentrated with heating. The resulting solid was
concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
Acetyl chloride (150 μL, 166 mg, 2.11 mmol) was added to the crude aniline hydrochloride
(146 mg, 0.47 mmol) in anhydrous acetonitrile (6.00 mL) and N,N-diisopropylethylamine (260
μL, 194 mg, 1.50 mmol) and the solution was stirred at rt. After 18 h, the solvent was
concentrated with heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (50 mL),
aqueous lithium hydroxide (3.0 M, 825 μL) was added, and the reaction stirred at rt. After 18
h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue
was purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH) to give 24a as a colorless
amorphous solid (58 mg, 56% over three steps): 1H NMR (DMSO-d6, 500 MHz) δ 10.94 (brs,
1H), 9.33 (s, 1H), 9.11 (s, 1H), 7.97 (d, J = 8.8 Hz, 1H), 6.94 (dd, J = 8.8, 2.2 Hz, 1H), 6.86
(d, J = 2.2 Hz, 1H), 2.13 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 170.6, 169.2, 162.9, 156.9,
145.5, 127.0, 123.8, 115.3, 114.8, 102.1, 23.3; IR (film) νmax 3406, 1626, 1599, 1556, 1385,
1254, 1204, 1192, 1097, 876, 837, 802 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C11H9NO4, 220.0610; found, 220.0599.
5.20 N-(7-Hydroxy-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (24b)
Compound 23b (1.01 g, 3.14 mmol) in glacial acetic acid (10.0 mL) and concentrated
hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted
with water (50 mL) and the solvent was concentrated with heating. The resulting solid was
concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride28 (830 mg,
3.00 mmol) in anhydrous acetonitrile (4.00 mL) was added to the crude aniline hydrochloride
(1.57 mmol) in anhydrous acetonitrile (8.0 mL) and N,N-diisopropylethylamine (2.00 mL, 1.49
g, 11.53 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with
heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (160 mL), aqueous lithium
hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 18 h, the reaction
was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was purified
via column chromatography (SiO2, 1:1 Hexanes:EtOAc to 2:1 EtOAc:Hexanes) and triturated
from Et2O to give 24b as a colorless amorphous solid (197 mg, 29% over three steps): 1H NMR
(DMSO-d6, 500 MHz) δ 10.94 (brs, 1H), 9.42 (brs, 1H), 9.00 (s, 1H), 7.99 (dd, J = 8.6, 2.5
Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 2.3 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.27 (d,
J = 8.8 Hz, 1H), 7.14-7.09 (m, 2H), 6.98 (dd, J = 8.8, 2.2 Hz, 1H), 6.96 (m, 1H), 6.92 (d, J =
2.2 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 171.4, 164.7, 162.9,
159.0, 159.0, 157.2, 148.2, 138.7, 129.9, 129.4, 129.0, 127.0, 125.7, 123.1, 121.7, 115.5, 115.2
(2C), 112.6, 111.6, 102.3, 55.9, 55.1; IR (film) νmax 3398, 2835, 1626, 1574, 1531, 1485, 1384,
1256, 1205, 1038, 1020, 837, 810, 729 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C24H19NO6, 418.1291; found, 418.1292.
5.21 N-(7-Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)acetamide (24c)
Compound 23b (1.01 g, 3.14 mmol) in glacial acetic acid (10.0 mL) and concentrated
hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted
with water (50 mL) and the solvent was concentrated with heating. The resulting solid was
concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
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Acetyl chloride (560 μL, 618 mg, 7.88 mmol) was added to the crude aniline hydrochloride
(1.57 mmol) in anhydrous acetonitrile (12.00 mL) and N,N-diisopropylethylamine (2.00 mL,
1.49 g, 11.53 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated
with heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (160 mL), aqueous lithium
hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 18 h, the reaction
was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was purified
via column chromatography (SiO2, 20:1 CH2Cl2:MeOH) to give 24c as a brown amorphous
solid (152 mg, 42% over three steps): 1H NMR (DMSO-d6, 500 MHz) δ 10.72 (brs, 1H), 9.33
(brs, 1H), 9.18 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 2.22 (s, 3H), 2.13 (s,
3H); 13C NMR (DMSO-d6, 125 MHz) δ 171.1, 169.2, 160.2, 155.0, 145.7, 123.5, 123.4, 115.0,
114.0, 110.9, 23.3, 7.9; IR (film) νmax 3256, 3128, 1657, 1626, 1607, 1589, 1556, 1431, 1391,
1342, 1313, 1283, 1205, 1182, 1155, 1068, 1051, 879, 824, 777, 604, 528 cm−1; HRMS
(ESI+) m/z: [M + H]+ calcd for C12H11NO4, 234.0766; found, 234.0763.
5.22 N-(7-Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)
benzamide (24d)
Compound 23b (991 mg, 3.23 mmol) in glacial acetic acid (10.0 mL) and concentrated
hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted
with water (50 mL) and the solvent was concentrated with heating. The resulting solid was
concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride28 (830 mg,
3.00 mmol) in anhydrous acetonitrile (4.00 mL) was added to the crude aniline hydrochloride
(1.61 mmol) in anhydrous acetonitrile (8.0 mL) and N,N-diisopropylethylamine (500 μL, 373
mg, 2.88 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with
heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (160 mL), aqueous lithium
hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 5 h, the reaction
was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was partially
purified via column chromatography (SiO2, 3:1 Hexanes:EtOAc to 2:1 Hexanes:EtOAc to 2:1
EtOAc:Hexanes) and triturated with Et2O to provide solid that was used without further
purificaiton.
Sodium hydroxide (161 mg, 4.03 mmol) was added to a solution of the solid (296 mg) in 1:1
MeOH:THF (15.0 mL). After 15 min, the solution was acidified to pH 1 with 6M aqueous HCl
and the solvent was concentrated. The residue was triturated with Et2O and the resulting solid
collected by filtration to give 24d as a yellow amorphous solid (87 mg, 14% over three
steps): 1H NMR (DMSO-d6, 500 MHz) δ 10.80 (brs, 1H), 9.41 (brs, 1H), 9.06 (s, 1H), 8.00
(dd, J = 8.6, 2.4 Hz, 1H), 7.93 (d, J = 2.3 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.37 (t, J = 7.9 Hz,
1H), 7.27 (d, J = 8.8 Hz, 1H), 7.13-7.10 (m, 2H), 7.05 (d, J = 8.8 Hz, 1H), 6.96 (ddd, J = 8.3,
2.6, 0.8 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.26 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ
171.8, 164.7, 160.4, 160.0, 160.0, 155.3, 148.3, 138.7, 129.9, 129.4, 129.1, 129.0, 125.7, 123.5,
122.8, 121.7, 115.2, 114.2, 112.6, 111.6, 111.1, 55.9, 55.1, 8.0; IR (film) νmax 1603, 1591,
1537, 1516, 1506, 1489, 1474, 1456, 1423, 1406, 1379, 1339, 1310, 1285, 1250, 1207, 1178,
1065, 1020, 779, 690 cm−1; HRMS (ESI+) m/z: [M + Na]+ calcd for C25H21NO6, 454.1267;
found, 454.1284.
5.23 N-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)acetamide (24e)
Compound 23c (1.00 g, 3.11 mmol) in glacial acetic acid (10.0 mL) and concentrated
hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted
with water (50 mL) and the solvent was concentrated with heating. The resulting solid was
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concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
Acetyl chloride (1.20 mL, 1.32 g, 16.88 mmol) was added to the crude aniline hydrochloride
(3.11 mmol) in anhydrous acetonitrile (24.0 mL) and N,N-diisopropylethylamine (3.00 mL,
2.24 g, 17.29 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated
with heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (320 mL), aqueous lithium
hydroxide (3.0 M, 5.50 mL) was added, and the reaction stirred at rt. After 18 h, the reaction
was acidified to pH 1 with 6M HCl, the solvent was concentrated, water (50 mL) was added,
and the solid was collected by filtration and washed with cold Et2O (50 mL). The residue was
purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH to 5:1 CH2Cl2:MeOH) to
give 24e as a beige amorphous solid (329 mg, 45% over three steps): 1H NMR (DMSO-d6,
500 MHz) δ 12.32 (brs, 1H), 10.97 (brs, 1H), 9.43 (brs, 1H), 9.04 (s, 1H), 6.39 (d, J = 2.0 Hz,
1H), 6.24 (d, J = 2.0 Hz, 1H), 2.12 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 175.3, 169.3,
164.5, 161.3, 156.9, 147.2, 122.3, 103.6, 98.8, 93.8, 23.2; IR (film) νmax 3346, 1630, 1593,
1448, 1364, 1277, 1258, 1200, 1182, 1024, 1003, 870, 843, 804, 797, 669, 652 cm−1; HRMS
(ESI+) m/z: [M + Na]+ calcd for C11H9NO5, 258.0378; found, 258.0379.
5.24 N-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide
(24f)
Compound 23c (1.00 g, 3.10 mmol) in glacial acetic acid (10.0 mL) and concentrated
hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted
with water (50 mL) and the solvent was concentrated with heating. The resulting solid was
concentrated from absolute EtOH (3 × 50 mL) and Et2O (100 mL) and used without further
purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride28 (1.77 g,
6.41 mmol) in anhydrous acetonitrile (8.00 mL) was added to the crude aniline hydrochloride
(3.10 mmol) in anhydrous acetonitrile (16.00 mL) and N,N-diisopropylethylamine (6.00 mL,
4.47 g, 34.59 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated
with heating, the residue was dissolved in 3:1:1 THF:H2O:MeOH (160 mL), aqueous lithium
hydroxide (3.0 M, 15.0 mL) was added, and the reaction stirred at rt. After 18 h, the reaction
was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was partially
purified via column chromatography (SiO2, 1:1 Hexanes:EtOAc). Sodium hydroxide (161 mg,
4.03 mmol) was added to a solution of the residue in 1:1 MeOH:THF (15.0 mL). After 15 min,
the solution was acidified to pH 1 with 6M aqueous HCl and the solvent was concentrated.
The residue was triturated with Et2O and the resulting solid collected by filtration to give
24f as a colorless amorphous solid (342 mg, 26% over three steps): 1H NMR (DMSO-d6, 500
MHz) δ 12.35 (brs, 1H), 11.02 (brs, 1H), 9.55 (s, 3H), 8.88 (s, 1H), 8.00 (dd, J = 8.6, 2.4 Hz,
1H), 7.95 (d, J = 2.4 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.13-7.09 (m,
2H), 6.96 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 6.27 (d, J = 2.1 Hz, 1H),
3.87 (s, 3H), 3.81 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 176.5, 165.1, 164.6, 161.4, 159.0,
159.0, 157.2, 150.8, 138.7, 130.0, 129.4, 129.1 (2C), 125.5, 121.7, 121.6, 115.2, 112.6, 111.6,
103.9, 99.1, 94.1, 55.9, 55.1; IR (film) νmax 3499, 3329, 3132, 2959, 2835, 1666, 1632, 1601,
1587, 1433, 1408, 1369, 1256, 1209, 1171, 1043, 1022, 872, 808.1, 741, 727, 692, 627
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C24H19NO7, 434.1240; found, 434.1233.
5.25 3-Acetamido-4-oxo-4H-chromen-7-yl acetate (25a)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21
mmol) were added in sequence to 24a (13 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
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cold Et2O to give 25a as a colorless amorphous solid (9 mg, 55%): 1H NMR (DMSO-d6, 500
MHz) δ 9.48 (brs, 1H), 9.26 (s, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.31
(dd, J = 8.8, 2.1 Hz, 1H), 2.34 (s, 3H), 2.15 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 170.9,
169.4, 168.7, 155.5, 154.6, 146.7, 126.7, 124.4, 120.0, 119.9, 111.5, 23.3, 20.9; IR (film)
νmax 3406, 3310, 3099, 1759, 1682, 1636, 1614, 1528, 1448, 1375, 1246, 1200, 1188, 1016,
721 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C13H11NO5, 262.0715; found, 262.0713.
5.26 3-(4-Methoxy-3-(3-methoxyphenyl)benzamido)-4-oxo-4H-chromen-7-yl acetate (25b)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21
mmol) were added in sequence to 24b (27 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
cold Et2O to give 25b as a colorless amorphous solid (19 mg, 65%): 1H NMR (DMSO-d6, 500
MHz) δ 9.56 (brs, 1H), 9.13 (s, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.02 (dd, J = 8.6, 2.4 Hz, 1H),
7.96 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.35 (dd, J = 8.8,
2.1 Hz, 1H), 7.28 (d, J = 8.8 Hz, 1H), 7.14-7.10 (m, 2H), 6.96 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H),
3.88 (s, 3H), 3.81 (s, 3H), 2.35 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 171.7, 168.7, 164.9,
159.1, 159.0, 155.8, 154.7, 149.8, 138.7, 130.0, 129.4, 129.1, 129.1, 126.7, 125.6, 123.7, 121.7,
120.3, 120.3, 115.2, 112.6, 111.7, 111.6, 55.9, 55.1, 20.9; IR (film) νmax 3439, 3381, 2939,
2837, 1769, 1634, 1616, 1531, 1502, 1481, 1443, 1367, 1267, 1238, 1204, 1180, 1136, 1095,
1036, 1020, 960, 874, 733, 696, 602 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C26H21NO7, 460.1396; found, 460.1396.
5.27 3-Acetamido-8-methyl-4-oxo-4H-chromen-7-yl acetate (25c)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21
mmol) were added in sequence to 24c (16 mg, 0.07 mmol) in anhydrous acetonitrile (500 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
cold Et2O to give 25c as a colorless amorphous solid (11 mg, 60%): 1H NMR (DMSO-d6, 500
MHz) δ 9.49 (brs, 1H), 9.32 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 2.39
(s, 3H), 2.27 (s, 3H), 2.16 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 171.2, 169.4, 168.6,
154.1, 152.6, 146.6, 124.2, 123.3, 120.1, 120.0, 120.0, 23.3, 20.6, 8.8; IR (film) νmax 3441,
1765, 1684, 1630, 1612, 1537, 1431, 1381, 1248, 1209, 1184, 1070, 1047, 897, 793, 781, 723
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C14H13NO5, 276.0872; found, 276.0868.
5.28 3-(4-Methoxy-3-(3-methoxyphenyl)benzamido)-8-methyl-4-oxo-4H-chromen-7-yl
acetate (25d)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21
mmol) were added in sequence to 24d (18 mg, 0.04 mmol) in anhydrous acetonitrile (500 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
cold Et2O to give 25d as a colorless amorphous solid (17 mg, 82%): 1H NMR (DMSO-d6, 500
MHz) δ 9.55 (brs, 1H), 9.19 (s, 1H), 8.04 (dd, J = 8.8, 0.5 Hz, 1H), 8.02 (dd, J = 8.8, 2.5 Hz,
1H), 7.96 (d, J = 2.4 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.28 (d, J =
8.8 Hz, 1H), 7.14-7.10 (m, 2H), 6.96 (ddd, J = 8.2, 2.5, 0.8 Hz, 1H), 3.88 (s, 3H), 3.81 (s, 3H),
2.41 (s, 3H), 2.31 (s, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 172.0, 168.6, 164.9, 159.1, 159.0,
154.3, 152.7, 149.6, 138.7, 130.0, 129.4, 129.1, 129.1, 125.6, 123.6, 123.3, 121.7, 120.4, 120.3,
120.2, 115.2, 112.6, 111.6, 55.9, 55.1, 20.6, 8.9; IR (film) νmax 3381, 2939, 2837, 1767, 1634,
1605, 1531, 1504, 1485, 1427, 1373, 1269, 1240, 1205, 1180, 1117, 1059, 1040, 1022, 901,
872, 824, 779, 733, 609, 590 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C27H23NO7,
474.1553; found, 474.1549.
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5.29 3-Acetamido-5-hydroxy-4-oxo-4H-chromen-7-yl acetate (25e)
N,N-diisopropylethylamine (17 μL, 13 mg, 0.10 mmol) and acetyl chloride (7 μL, 8 mg, 0.10
mmol) were added in sequence to 24e (22 mg, 0.07 mmol) in anhydrous acetonitrile (600 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
cold Et2O. The residue was purified by PTLC (SiO2, 40:1 CH2Cl2:MeOH then 80:1
CH2Cl2:MeOH) to give 25e as a colorless amorphous solid (4 mg, 14%): 1H NMR (CDCl3,
500 MHz) δ 11.95 (brs, 1H), 9.34 (s, 1H), 7.86 (brs, 1H), 6.80 (d, J = 2.2 Hz, 1H), 6.59 (d, J
= 2.2 Hz, 1H), 2.34 (s, 3H), 2.25 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ 175.4, 168.9, 168.5,
161.7, 156.5, 156.4, 146.0, 123.5, 108.1, 105.2, 101.6, 24.3, 21.4; IR (film) νmax 3341, 2918,
2849, 1759, 1655, 1620, 1595, 1547, 1537, 1479, 1402, 1369, 1346, 1279, 1213, 1171, 1124,
1063, 1024, 1011, 989, 889, 800, 766, 742, 716, 702 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd
for C13H11NO6, 278.0665; found, 278.0672.
5.30 5-Hydroxy-3-(4-methoxy-3-(3-methoxyphenyl)benzamido)-4-oxo-4H-chromen-7-yl
acetate (25f)
N,N-diisopropylethylamine (17 μL, 13 mg, 0.10 mmol) and acetyl chloride (7 μL, 8 mg, 0.10
mmol) were added in sequence to 24f (36 mg, 0.08 mmol) in anhydrous acetonitrile (600 μL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration and washed with
cold Et2O. The residue was purified by column chromatography (SiO2, CH2Cl2 to 200:1
CH2Cl2:MeOH) to give 25f as a colorless amorphous solid (11 mg, 28%): 1H NMR (CDCl3,
500 MHz) δ 11.99 (brs, 1H), 9.53 (s, 1H), 8.61 (brs, 1H), 7.94 (dd, J = 8.6, 2.4 Hz, 1H), 7.90
(d, J = 2.4 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.13 (m, 1H), 7.10 (m, 1H), 7.09 (d, J = 8.9 Hz,
1H), 6.94 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.83 (d, J = 2.0 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H),
2.35 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ 175.6, 168.5, 165.1, 161.7, 160.0, 159.5, 156.5,
156.5, 146.0, 138.8, 131.3, 130.2, 129.4, 128.6, 125.8, 123.8, 122.2, 115.5, 113.3, 111.3, 108.1,
105.2, 101.7, 56.1, 55.5, 21.4; IR (film) νmax 3379, 3113, 2934, 2841, 1761, 1672, 1649, 1624,
1605, 1580, 1541, 1508, 1485, 1294, 1350, 1273, 1252, 1244, 1229, 1211, 1186, 1163, 1123,
1057, 1026, 893, 874, 768, 756, 729, 689 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C26H21NO8, 476.1346; found, 476.1336.
5.31 N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-4-oxo-4H-chromen-3-yl)acetamide (26a)
Boron trifluoride etherate (50 μL, 0.41 mmol) was added to 24a (46 mg, 0.21 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (116 mg, 0.32 mmol) in anhydrous CH2Cl2 (6.00 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
3 × 10:1 CH2Cl2:MeOH) to give 26a as a colorless amorphous solid (6 mg, 7% over two
steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 9.26 (brs, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.11 (d,
J = 2.3 Hz, 1H), 7.02 (dd, J = 8.9, 2.3 Hz, 1H), 5.57 (d, J = 2.0 Hz, 1H), 4.13-4.07 (m, 2H),
3.57 (s, 3H), 3.32 (d, J = 9.1 Hz, 1H), 2.20 (s, 3H), 1.33 (s, 3H), 1.09 (s, 3H); 13C NMR
(CDCl3/MeOD, 125 MHz) δ 171.6, 169.4, 161.5, 157.5, 145.3, 127.3, 124.2, 116.7, 115.9,
103.4, 98.5, 84.2, 79.0, 71.0, 68.3, 62.0, 28.9, 23.9, 22.7; IR (film) νmax 3371, 3312, 2980,
2930, 1670, 1628, 1612, 1528, 1447 1377, 1244, 1200, 1144, 1128, 1113, 1092, 1055, 1022,
986, 968, 949, 779, 734, 658 cm−1; HRMS (ESI+) m/z: [M + Na]+ calcd for C19H23NO8,
416.1321; found, 416.1302.
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Boron trifluoride etherate (65 μL, 0.53 mmol) was added to 24b (103 mg, 0.25 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (141 mg, 0.39 mmol) in anhydrous CH2Cl2 (7.90 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 1:1 Hexanes:EtOAc)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (400 μL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via column
chromatography (SiO2, 8:1 CH2Cl2:MeOH) then PTLC (SiO2, 8:1 CH2Cl2:Acetone then 8:1
CH2Cl2:MeOH) to give 26b as a colorless amorphous solid (4 mg, 3% over two steps): 1H
NMR (CDCl3/MeOD, 400 MHz) δ 9.45 (s, 1H), 8.82 (brs, 1H), 8.13 (d, J = 8.9 Hz, 1H), 7.91
(dd, J = 8.6, 2.4 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.15 (d, J = 2.3 Hz,
1H), 7.09 (m, 1H), 7.07-7.01 (m, 3H), 6.89 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 5.59 (d, J = 2.0 Hz,
1H), 4.15-4.08 (m, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.57 (s, 3H), 3.33 (d, J = 9.0 Hz, 1H), 1.34
(s, 3H), 1.10 (s, 3H); 13C NMR (CDCl3/MeOD, 125 MHz) δ 171.8, 165.4, 161.5, 159.8, 159.4,
157.5, 145.1, 138.8, 131.1, 130.2, 129.3, 128.5, 127.3, 125.9, 124.4, 122.1, 116.5, 115.9, 115.3,
113.2, 111.2, 103.5, 98.5, 84.2, 79.0, 71.0, 68.3, 62.0, 56.0, 55.4, 28.9, 22.7; IR (film) νmax
3439, 3416, 3377, 2974, 2934, 2835, 1666, 1632, 1605, 1531, 1504, 1481, 1447, 1367, 1265,
1244, 1207, 1130, 1113, 1092, 1053, 1038, 1022, 991, 968, 949, 737, 698 cm−1; HRMS
(ESI+) m/z: [M + H]+ calcd for C32H33NO10, 592.2183; found, 592.2181.
5.33 N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-8-methyl-4-oxo-4H-chromen-3-yl)acetamide (26c)
Boron trifluoride etherate (60 μL, 0.49 mmol) was added to 24c (52 mg, 0.22 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (120 mg, 0.33 mmol) in anhydrous CH2Cl2 (7.30 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 20:1 CH2Cl2:MeOH)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (400 μL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
10:1 CH2Cl2:MeOH then EtOAc) to give 26c as a colorless amorphous solid (7 mg, 8% over
two steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 9.30 (s, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.28
(d, J = 9.1 Hz, 1H), 5.60 (d, J = 1.9 Hz, 1H), 4.17-4.12 (m, 2H), 3.57 (s, 3H), 3.33 (d, J = 9.0
Hz, 1H), 2.24 (s, 3H), 2.19 (s, 3H), 1.32 (s, 3H), 1.06 (s, 3H); 13C NMR (CDCl3/MeOD, 125
MHz) δ 172.1, 169.4, 158.9, 155.2, 145.5, 124.3, 123.7, 116.5, 114.8, 112.2, 98.3, 84.3, 78.9,
71.2, 68.5, 62.0, 29.1, 23.9, 22.5, 8.4; IR (film) νmax 3499, 3379, 3360, 2924, 1605, 1531, 1427,
1385, 1261, 1194, 1130, 1113, 1070, 1051, 987, 970, 949, 876, 804, 781, 729, 700, 648
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C20H25NO8, 408.1659; found, 408.1671.
5.34 N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-8-methyl-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (26d)
Boron trifluoride etherate (31 μL, 0.25 mmol) was added to 24d (52 mg, 0.12 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (69 mg, 0.19 mmol) in anhydrous CH2Cl2 (3.70 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 1:1 Hexanes:EtOAc)
and the coupled carbonate was used without further purification.
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Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1:1 CH2Cl2:MeOH:Acetone) to give 26d as a colorless amorphous solid (17 mg, 23% over
two steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 9.51 (brs, 1H), 8.83 (brs, 1H), 8.08 (d, J =
9.0 Hz, 1H), 7.93 (m, 1H), 7.90 (m, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.32 (d, J = 9.1 Hz, 1H),
7.11 (m, 1H), 7.08 (m, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.91 (m, 1H), 5.64 (m, 1H0, 4.22-4.17
(m, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.60 (s, 3H), 3.37 (d, J = 8.7 Hz, 1H), 2.30 (s, 3H), 1.35 (s,
3H), 1.10 (s, 3H); 13C NMR (CDCl3/MeOD, 125 MHz) δ 172.3, 165.4, 159.8, 159.4, 158.9,
155.3, 145.2, 138.8, 131.1, 130.2, 129.3, 128.5, 126.0, 124.4, 124.1, 122.2, 116.5, 115.4, 114.9,
113.3, 112.2, 111.2, 98.2, 84.4, 78.9, 71.2, 68.6, 62.1, 56.0, 55.5, 29.2, 22.6, 8.5; IR (film)
νmax 3434, 3055, 2974, 2935, 2835, 2502, 1630, 1605, 1533, 1502, 1483, 1421, 1369, 1265,
1217, 1194, 1136, 1113, 1068, 1094, 1024, 991, 970, 939, 876, 781, 735, 700 cm−1; HRMS
(ESI+) m/z: [M + H]+ calcd for C33H35NO10, 606.2339; found, 606.2349.
5.35 N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-5-hydroxy-4-oxo-4H-chromen-3-yl)acetamide (26e)
Boron trifluoride etherate (53 μL, 0.43 mmol) was added to 24e (52 mg, 0.22 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (120 mg, 0.33 mmol) in anhydrous CH2Cl2 (7.00 mL).
After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 50:1 CH2Cl2:MeOH)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1 CH2Cl2:MeOH then 50:50:1:1 CH2Cl2:EtOAc:MeOH:Acetone) to give 26e as a colorless
amorphous solid (4 mg, 5% over two steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 9.19 (brs,
1H), 6.60 (m, 1H), 6.43 (m, 1H), 5.53 (m, 1H), 4.11-4.05 (m, 2H), 3.57 (s, 3H), 3.31 (d, J =
9.2 Hz, 1H), 2.20 (s, 3H), 1.33 (s, 3H), 1.10 (s, 3H); 13C NMR (CDCl3/MeOD, 125 MHz) δ
175.0, 169.2, 163.0, 161.4, 157.3, 145.8, 122.9, 105.5, 100.0, 98.3, 94.9, 84.2, 78.9, 71.0, 68.3,
62.0, 28.9, 23.9, 22.7; IR (film) νmax 3377, 2974, 2930, 2851, 1657, 1620, 1591, 1537, 1497,
1464, 1447, 1412, 1367, 1352, 1288, 1180, 1117, 1057, 1026, 997, 951, 806, 764, 739 cm−1;
HRMS (ESI+) m/z: [M + H]+ calcd for C19H23NO9, 410.1451; found, 410.1454.
5.36 N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy)-5-hydroxy-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamid e (26f)
Boron trifluoride etherate (20 μL, 0.16 mmol) was added to 24f (22 mg, 0.05 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (51 mg, 0.14 mmol) in anhydrous CH2Cl2 (2.00 mL).
After stirring at rt for 18 h, triethylamine (30 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 1:1 Hexanes:EtOAc)
and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1:1 CH2Cl2:MeOH:Acetone) to give 26f as a colorless amorphous solid (2 mg, 7% over
two steps):1H NMR (CDCl3, 500 MHz) δ 11.95 (s, 1H), 9.45 (s, 1H), 8.63 (s, 1H), 7.93 (dd,
J = 8.6, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.13 (m, 1H), 7.10 (dd,
J = 2.5, 1.6 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 6.94 (ddd, J = 8.3, 2.7, 0.9 Hz, 1H), 6.67 (d, J
= 2.1 Hz, 1H), 6.49 (d, J = 2.1 Hz, 1H), 5.63 (d, J = 1.6 Hz, 1H), 4.23-4.19 (m, 2H0, 3.91 (s,
3H), 3.87 (s, 3H), 3.61 (s, 3H), 3.37 (m, 1H), 2.66 (brs 1H), 2.59 (brs, 1H), 1.39 (s, 3H), 1.16
(s, 3H); 13C NMR (CDCl3, 125 MHz) δ 175.2, 165.1, 162.9, 161.7, 159.9, 159.5, 157.4, 145.4,
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138.8, 131.2, 130.2, 129.4, 128.5, 125.8, 123.3, 122.2, 115.5, 113.3, 111.2, 105.5, 100.1, 97.8,
95.0, 84.3, 79.0, 71.1, 68.4, 62.2, 56.1, 55.5, 29.3, 22.7; IR (film) νmax 3385, 2938, 2851, 1655,
1622, 1591, 1535, 1502, 1477, 1466, 1356, 1285, 1277, 1248, 1213, 1180, 1117, 1055, 1022,
949, 910, 806, 762, 731 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C32H33NO11, 608.2132;
found, 608.2109.
5.37 2-(Benzo[d][1,3]dioxol-5-yl)-1-(2,4-dihydroxyphenyl)ethanone (29a)41
Resorcinol (2.21 g, 20.05 mmol) and 3,4-(methylenedioxy)phenylacetonitrile (3.12 g, 19.36
mmol) in EtOAc (60 mL) was cooled to 0° C. After 15 min, zinc chloride (1.47 g, 10.77 mmol)
was added, hydrochloric acid was bubbled through the solution for 10 min, and the reaction
vessel was sealed and warmed to rt over 18 h. The solvent was decanted away, water (25 mL)
was added to the resulting oil, and the solution was then heated to reflux for 3 h. After cooling
to rt, the solution was extracted with EtOAc (3 × 50 mL). The organic layers were dried
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography
(SiO2, 2:1 Hexanes:EtOAc) to give 29a as a yellow amorphous solid (1.17 g, 22%): 1H NMR
(DMSO-d6, 500 MHz) δ 12.52 (brs, 1H), 10.69 (brs, 1H), 7.94 (d, J = 8.9 Hz, 1H), 6.87 (d, J
= 1.6 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 6.75 (dd, J = 7.9, 1.6 Hz, 1H), 6.39 (dd, J = 8.8, 2.3
Hz, 1H), 6.25 (d, J = 2.4 Hz, 1H), 5.98 (s, 2H), 4.20 (s, 2H).
5.38 2-(Benzo[d][1,3]dioxol-5-yl)-1-(2,4-dihydroxy-3-methylphenyl)ethanone (29b)41
2-Methylresorcinol (2.51 g, 20.19 mmol) and 3,4-(methylenedioxy)phenylacetonitrile (3.12 g,
19.37 mmol) in EtOAc (40 mL) was cooled to 0° C. After 15 min, zinc chloride (1.48 g, 10.89
mmol) was added, hydrochloric acid was bubbled through the solution for 10 min, and the
reaction vessel was sealed and warmed to rt over 18 h. The solvent was decanted away, water
(25 mL) was added to the resulting oil, and the solution was then heated to reflux for 3 h. After
cooling to rt, the solution was extracted with EtOAc (3 × 50 mL). The organic layers were
dried (Na2SO4), filtered, and concentrated. Recrystallization from MeOH gave 29b as a yellow
amorphous solid (1.40 g, 25%): 1H NMR (DMSO-d6, 500 MHz) δ 12.97 (brs, 1H), 10.59 (brs,
1H), 7.83 (d, J = 8.9 Hz, 1H), 6.87 (d, J = 1.6 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 6.75 (dd, J =
7.9, 1.6 Hz, 1H), 6.48 (d, J = 8.9 Hz, 1H), 5.98 (s, 2H), 4.20 (s, 2H), 1.96 (s, 3H).
5.39 3-(Benzo[d][1,3]dioxol-5-yl)-7-hydroxy-4H-chromen-4-one (30a)41
Boron trifluoride etherate (3.21 mL, 26.01 mmol) was added to 29a (1.11 g, 4.06 mmol) in
anhydrous N,N-dimethylformamide (16.0 mL) at rt. After 10 min, methanesulfonyl chloride
(1.31 mL, 1.94 g, 16.93 mmol) was added and the reaction was then heated to 90° C for 5 d.
After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration
to give 30a as a reddish-brown amorphous solid (1.08 g, 94%): 1H NMR (DMSO-d6, 500 MHz)
δ 10.83 (brs, 1H), 8.36 (s, 1H), 7.98 (d, J = 8.8 Hz, 1H), 7.15 (d, J = 1.7 Hz, 1H), 7.06 (dd, J
= 8.0, 1.7 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.95 (dd, J = 8.8, 2.2 Hz, 1H), 6.88 (d, J = 2.2 Hz,
1H), 6.06 (s, 2H).
5.40 3-(Benzo[d][1,3]dioxol-5-yl)-7-hydroxy-8-methyl-4H-chromen-4-one (30b)41
Boron trifluoride etherate (3.35 mL, 27.14 mmol) was added to 29b (1.21 g, 4.24 mmol) in
anhydrous N,N-dimethylformamide (16.5 mL) at rt. After 10 min, methanesulfonyl chloride
(1.36 mL, 2.01 g, 17.57 mmol) was added and the reaction was then heated to 90° C for 5 d.
After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration
to give 30b as a reddish-brown amorphous solid (1.16 g, 93%): 1H NMR (DMSO-d6, 500
MHz) δ 10.69 (brs, 1H), 8.44 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.16 (d, J = 1.7 Hz, 1H), 7.07
(dd, J = 8.0, 1.7 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H), 2.24
(s, 3H).
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5.41 3-(Benzo[d][1,3]dioxol-5-yl)-4-oxo-4H-chromen-7-yl acetate (31a)
N,N-diisopropylethylamine (40 μL, 30 mg, 0.23 mmol) and acetyl chloride (40 μL, 44 mg, 0.56
mmol) were added in sequence to 30a (51 mg, 0.18 mmol) in anhydrous acetonitrile (1.30 mL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration. The residue was
purified via column chromatography (SiO2, 2:1 Hexanes:EtOAc) to give 31a as a brown
amorphous solid (26 mg, 45%): 1H NMR (CDCl3, 500 MHz) δ 8.33 (d, J = 8.8 Hz, 1H), 7.98
(s, 1H), 7.31 (d, J = 2.1 Hz, 1H), 7.18 (dd, J = 8.8, 2.2 Hz, 1H), 7.10 (d, J = 1.7 Hz, 1H), 6.99
(dd, J = 7.9, 1.7 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H), 2.37 (s, 3H); 13C NMR
(CDCl3, 125 MHz) δ 175.8, 168.8, 156.8, 154.6, 153.0, 148.0, 147.9, 128.1, 125.5, 125.4,
122.6, 119.7, 111.1, 109.9, 108.7, 101.4, 21.4; IR (film) νmax 3506, 3086, 2905, 1753, 1732,
1641, 1620, 1499, 1439, 1381, 1335, 1283, 1242, 1229, 1177, 1146, 1049, 1032, 1016, 959,
939, 930, 908, 854, 818, 795, 775 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C18H12O6,
325.0712; found, 325.0702.
5.42 3-(Benzo[d][1,3]dioxol-5-yl)-8-methyl-4-oxo-4H-chromen-7-yl acetate (31b)
N,N-diisopropylethylamine (40 μL, 30 mg, 0.23 mmol) and acetyl chloride (40 μL, 44 mg, 0.56
mmol) were added in sequence to 30b (51 mg, 0.17 mmol) in anhydrous acetonitrile (1.30 mL)
and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction
was diluted with water (5 mL) and the precipitate was collected by filtration to give 31b as a
brown amorphous solid (35 mg, 60%): 1H NMR (DMSO-d6, 500 MHz) δ 8.59 (s, 1H), 8.03
(d, J = 8.6 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.18 (d, J = 1.7 Hz, 1H), 7.10 (dd, J = 8.0, 1.7
Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 6.07 (s, 2H), 2.40 (s, 3H), 2.28 (s, 3H); 13C NMR (DMSO-
d6, 125 MHz) δ 175.0, 168.6, 154.6, 154.3, 152.2, 147.1, 147.1, 125.3, 123.7, 122.5, 121.7,
120.2, 119.9, 109.4, 108.2, 101.1, 20.6, 8.9; IR (film) νmax 3074, 2897, 1763, 1643, 1603, 1582,
1504, 1489, 1425, 1371, 1335, 1281, 1252, 1227, 1205, 1184, 1146, 1107, 1068, 1038, 1013,
928, 901, 864, 851, 810, 733 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C19H14O6, 339.0869;
found, 339.0861.
5.43 3-(Benzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl acetate (31c)
N,N-diisopropylethylamine (65 μL, 48 mg, 0.37 mmol) and acetyl chloride (25 μL, 28 mg, 0.35
mmol) were added in sequence to 3-(benzo[d][1,3]dioxol-5-yl)-5,7-dihydroxy-4H-chromen-4-
one31 (104 mg, 0.35 mmol) in anhydrous acetonitrile (2.50 mL) and the solution was then
heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (10
mL), the precipitate was collected by filtration and washed with cold Et2O (3 × 10 mL). The
residue was purified via column chromatography (SiO2, 3:1 CH2Cl2:Hex to CH2Cl2 to 100:1
CH2Cl2:MeOH) to give 31c as a colorless amorphous solid (10 mg, 9%): 1H NMR (DMSO-
d6, 500 MHz) δ 12.90 (brs, 1H), 8.57 (s, 1H), 7.17 (d, J = 1.6 Hz, 1H), 7.09 (dd, J = 8.1, 1.8
Hz, 1H), 7.04-7.01 (m, 2H), 6.71 (d, J = 2.1 Hz, 1H), 6.08 (s, 2H), 2.32 (s, 3H); 13C NMR
(DMSO-d6, 125 MHz) δ 180.7, 168.4, 161.3, 156.4, 155.9, 147.3, 147.1, 124.0, 122.7, 122.6,
109.4, 108.7, 108.3, 105.5, 101.4, 101.2, 20.9; IR (film) νmax 3076, 2907, 1747, 1661, 1614,
1585, 1504, 1487, 1435, 1367, 1335, 1308, 1296, 1275, 1250, 1236, 1219, 1200, 1175, 1144,
1126, 1103, 1061, 1042, 930, 891, 872, 820, 812, 785, 725, 698, 667 cm−1; HRMS (ESI+) m/
z: [M + H]+ calcd for C18H12O7, 341.0661; found, 341.0672.
5.44 3-(Benzo[d][1,3]dioxol-5-yl)-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-
tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (32a)
Boron trifluoride etherate (88 μL, 0.71 mmol) was added to 30a (102 mg, 0.36 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (134 mg, 0.37 mmol) in anhydrous CH2Cl2 (11.60 mL).
After stirring at rt for 18 h, triethylamine (100 μL) was added and the solvent was concentrated.
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The residue was partially purified via column chromatography (SiO2, 2:1 Hexanes:EtOAc to
4:1:1 Hexanes:CH2Cl2:EtOAc) and the coupled carbonate was used without further
purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1 CH2Cl2:MeOH then 20:20:1:1 CH2Cl2:EtOAc:MeOH:Acetone then 10:1 Et2O:Acetone)
to give 32a as a colorless amorphous solid (1 mg, 1% over two steps): 1H NMR (CDCl3, 500
MHz) δ 8.22 (d, J = 8.9 Hz, 1H), 7.93 (s, 1H), 7.12 (d, J = 2.3 Hz, 1H), 7.10 (d, J = 1.7 Hz,
1H), 7.06 (dd, J = 8.9, 2.3 Hz, 1H), 6.98 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H),
6.00 (s, 2H), 5.67 (d, J = 1.5 Hz, 1H), 4.26-4.21 (m, 2H), 3.62 (s, 3H), 3.39 (d, J = 8.9 Hz, 1H),
2.64 (brs 1H), 2.57 (brs, 1H), 1.40 (s, 3H), 1.16 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ 176.0,
161.0, 157.8, 152.6, 147.9, 147.9, 128.1, 125.8, 125.2, 122.6, 119.3, 115.6, 110.0, 108.6, 103.4,
101.4, 98.0, 84.3, 79.0, 71.2, 68.3, 62.2, 29.4, 22.7; IR (film) νmax 3414, 2926, 2854, 1622,
1568, 1504, 1489, 1439, 1385, 1367, 1335, 1248, 1198, 1113, 1092, 1034, 987, 968, 926, 854,




Boron trifluoride etherate (88 μL, 0.71 mmol) was added to 30b (100 mg, 0.34 mmol) and
(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]
pyran-4-yl 2,2,2-trichloroacetimidate (134 mg, 0.37 mmol) in anhydrous CH2Cl2 (11.60 mL).
After stirring at rt for 18 h, triethylamine (100 μL) was added and the solvent was concentrated.
The residue was partially purified via column chromatography (SiO2, 2:1 Hexanes:EtOAc to
4:1:1 Hexanes:CH2Cl2:EtOAc) and the coupled carbonate was used without further
purification.
Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1 CH2Cl2:MeOH then 20:20:1:1 CH2Cl2:EtOAc:MeOH:Acetone then 10:1 Et2O:Acetone)
to give 32b as a colorless amorphous solid (3 mg, 2% over two steps): 1H NMR (CDCl3/
CD3OD, 500 MHz) δ 8.06 (d, J = 8.9 Hz, 1H), 7.97 (s, 1H), 7.28 (m, 1H), 7.03 (d, J = 1.7 Hz,
1H), 6.92 (dd, J = 8.0, 1.7 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 5.95 (s, 2H), 5.60 (d, J = 1.5 Hz,
1H), 4.17-4.11 (m, 2H), 3.57 (s, 3H), 3.33 (m, 1H), 2.25 (s, 3H0, 1.32 (s, 3H), 1.06 (s,
3H); 13C NMR (CDCl3/CD3OD, 125 MHz) δ 176.9, 158.6, 155.6, 153.0, 147.8, 147.7, 125.7,
124.8, 124.5, 122.5, 118.8, 114.5, 112.1, 109.9, 108.5, 101.3, 98.2, 84.4, 78.8, 71.2, 68.6, 62.0,
29.1, 22.5, 8.4; IR (film) νmax 3396, 2928, 1636, 1618, 1597, 1504, 1489, 1427, 1381, 1337,
1267, 1250, 1231, 1196, 1132, 1111, 1072, 1053, 1041, 993, 962, 924, 808, 785, 770, 735
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C25H26O9, 471.1655; found, 471.1666.
5.46 3-(Benzo[d][1,3]dioxol-5-yl)-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-
tetrahydro-2H-pyran-2-yloxy)-5-hydroxy-4H-chromen-4-one (32c)
Boron trifluoride etherate (83 μL, 0.67 mmol) was added to 3-(benzo[d][1,3]dioxol-5-yl)-5,7-
dihydroxy-4H-chromen-4-one31 (100 mg, 0.34 mmol) and (3aR,4S,7R,7aR)-7-methoxy-6,6-
dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]pyran-4-yl 2,2,2-trichloroacetimidate
(178 mg, 0.49 mmol) in anhydrous CH2Cl2 (11.10 mL). After stirring at rt for 18 h,
triethylamine (60 μL) was added and the solvent was concentrated. The residue was partially
purified via column chromatography (SiO2, 50:1 CH2Cl2:MeOH) and the coupled carbonate
was used without further purification.
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Carbonate was added to MeOH (4.0 mL), CH2Cl2 (1.0 mL), and triethylamine (400 μL) and
stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO2,
20:1 CH2Cl2:MeOH then 20:1:1 CH2Cl2:MeOH:Acetone then 40:40:1:1
CH2Cl2:EtOAc:MeOH:Acetone) to give 32c as a colorless amorphous solid (7 mg, 4% over
two steps): 1H NMR (CDCl3/MeOD, 500 MHz) δ 7.85 (s, 1H), 6.99 (d, J = 1.6 Hz, 1H), 6.90
(dd, J = 8.0, 1.7 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 6.44 (d, J = 2.2
Hz, 1H), 5.96 (s, 2H), 5.54 (d, J = 2.1 Hz, 1H), 4.09 (dd, J = 9.4, 3.4 Hz, 1H), 4.06 (m, 1H),
3.56 (s, 3H), 3.30 (d, J = 9.4 Hz, 1H), 1.32 (s, 3H), 1.10 (s, 3H); 13C NMR (CDCl3/MeOD,
125 MHz) δ 180.9, 162.6, 162.2, 158.9, 153.3, 148.0, 147.9, 124.4, 124.0, 122.6, 109.7, 108.7,
106.8, 101.4, 100.2, 98.3, 94.6, 84.2, 78.9, 71.0, 68.3, 62.0, 28.9, 22.7; IR (film) νmax 3410,
2980, 2920, 2849, 1722, 1655, 1614, 1574, 1504, 1493, 1470, 1435, 1369, 1308, 1271, 1248,
1209, 1194, 1180, 1157, 1117, 1038, 995, 955, 922, 847, 822, 783, 737 cm−1; HRMS (ESI+)
m/z: [M + H]+ calcd for C24H24O10, 473.1448; found, 473.1427.
5.47 7-(Allyloxy)-3-(benzo[d][1,3]dioxol-5-yl)-4H-chromen-4-one (33a)
N,N-Diisopropylethylamine (645 μL, 481 mg, 3.72 mmol) and allyl bromide (644 μL, 900 mg,
7.44 mmol) were sequentially added to 30a (700 mg, 2.48 mmol) in anhydrous N,N-
dimethylformamide (3.5 mL) and anhydrous acetonitrile (12.40 mL) and the resulting solution
was then heated to reflux for 4 h. After cooling to rt, the reaction was poured into water and
the precipitate was collected by filtration. The residue was purified via column chromatography
(SiO2, 4:1:1 Hexanes:CH2Cl2:EtOAc) to give 33a as a colorless amorphous solid (418 mg,
52%): 1H NMR (CDCl3, 500 MHz) δ 8.22 (d, J = 8.9 Hz, 1H), 7.92 (s, 1H), 7.11 (d, J = 1.7
Hz, 1H), 7.02 (dd, J = 8.9, 2.4 Hz, 1H), 6.98 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H),
6.87 (d, J = 2.4 Hz, 1H), 6.08 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 6.00 (s, 3H), 5.47 (dq, J = 17.3,
1.5 Hz, 1H), 5.37 (dq, J = 10.5, 1.5 Hz, 1H), 4.66 (dt, J = 5.3, 1.5 Hz, 2H); 13C NMR
(CDCl3, 125 MHz) δ 175.9, 163.1, 158.0, 152.4, 147.9, 147.8, 132.3, 128.1, 125.9, 122.6,
118.8, 118.6, 115.2, 110.0, 108.6, 101.4, 101.3; IR (film) νmax 3080, 2885, 1628, 1597, 1566,
1502, 1487, 1443, 1423, 1387, 1371, 1333, 1286, 1269, 1250, 1202, 1097, 1036, 937, 924,
852, 818, 781 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C19H14O5, 323.0919; found,
323.0915.
5.48 7-(Allyloxy)-3-(benzo[d][1,3]dioxol-5-yl)-8-methyl-4H-chromen-4-one (33b)
N,N-Diisopropylethylamine (645 μL, 481 mg, 3.72 mmol) and allyl bromide (644 μL, 900 mg,
7.44 mmol) were sequentially added to 30b (702 mg, 2.37 mmol) in anhydrous N,N-
dimethylformamide (6.5 mL) and anhydrous acetonitrile (12.40 mL) and the resulting solution
was then heated to reflux for 4 h. After cooling to rt, the reaction was poured into water (150
mL) and was extracted with CH2Cl2 (3 × 200 mL) and EtOAc (200 mL). The organic layers
were dried (Na2SO4), filtered, and concentrated. The residue was purified via column
chromatography (SiO2, 4:1:1 Hexanes:CH2Cl2:EtOAc) to give 33b as a colorless amorphous
solid (199 mg, 25%): 1H NMR (CDCl3, 500 MHz) δ 8.14 (d, J = 8.9 Hz, 1H), 7.99 (s, 1H),
7.12 (d, J = 1.7 Hz, 1H), 7.00 (d, J = 8.9 Hz, 1H), 6.99 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J =
8.0 Hz, 1H), 6.10 (ddt, J = 17.2, 10.6, 5.1 Hz, 1H), 6.00 (s, 2H), 5.47 (dq, J = 17.2, 1.5 Hz,
1H), 5.34 (dq, J = 10.6, 1.5 Hz, 1H), 4.70 (dt, J = 5.1, 1.5 Hz, 2H), 2.37 (s, 3H); 13C NMR
(CDCl3, 125 MHz) δ 176.6, 160.5, 155.7, 152.8, 147.9, 147.8, 132.8, 126.1, 125.0, 124.5,
122.6, 118.6, 114.5, 110.1, 110.0, 108.6, 101.4, 69.6, 8.4; IR (film) νmax 3076, 3016, 2995,
2918, 1641, 1620, 1601, 1504, 1493, 1427, 1389, 1337, 1281, 1252, 1232, 1202, 1144, 1115,
1084, 1072, 1038, 997, 935, 922, 851, 800, 783 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for
C20H16O5, 337.1076; found, 337.1067.
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N,N-diethylaniline (460 μL) was added to 33a (392 mg, 1.22 mmol) in a sealed flask and the
solution was then heated to 170° C for 48 h. The reaction was diluted with 1M aqueous HCl
solution (50 mL) and CH2Cl2 (50 mL). The organic layers were washed with 1M aqueous HCl
solution (3 × 50 mL), dried (Na2SO4), filtered, and concentrated. The residue was purified via
column chromatography (SiO2, 8:1:1 Hexanes:CH2Cl2:EtOAc to 4:1:1
Hexanes:CH2Cl2:EtOAc) then PTLC (SiO2, 2:1:1 Hexanes:CH2Cl2:EtOAc) to give 6-allyl
34a as a near-colorless amorphous solid (3 mg, 1%): 1H NMR (CDCl3, 500 MHz) δ 8.06 (s,
1H), 7.90 (s, 1H), 7.09 (d, J = 1.7 Hz, 1H), 6.97 (dd, J = 6.3, 1.7 Hz, 1H), 6.89-6.86 (m, 2H),
6.05 (m, 1H), 5.99 (s, 2H), 5.24 (m, 1H), 5.21 (dq, J = 6.8, 1.4 Hz, 1H), 3.53 (d, J = 6.4 Hz,
2H); 13C NMR (CDCl3, 125 MHz) δ 176.1, 159.6, 156.9, 152.5, 147.9, 147.8, 135.7, 128.1,
125.9, 125.2, 125.1, 122.6, 118.5, 117.7, 110.0, 108.6, 103.4, 101.4, 35.0; IR (film) νmax 3076,
2953, 2918, 2872, 2851, 1620, 1574, 1504, 1495, 1435, 1404, 1371, 1319, 1275, 1252, 1240,
1151, 1138, 1042, 912, 858, 768 cm−1; HRMS (ESI+) m/z: [M + Na]+ calcd for C19H14O5,
345.0739; found, 345.0744.
5.50 6-Allyl-3-(benzo[d][1,3]dioxol-5-yl)-7-hydroxy-8-methyl-4H-chromen-4-one (34b)
N,N-diethylaniline (210 μL) was added to 33b (180 mg, 0.53 mmol) in a sealed flask and the
solution was then heated to 170° C for 48 h. The reaction was diluted with 1M aqueous HCl
solution (10 mL) and the precipitate was collected by filtration. The residue was purified via
column chromatography (SiO2, 8:1:1 Hexanes:CH2Cl2:EtOAc to 4:1:1
Hexanes:CH2Cl2:EtOAc) to give 6-allyl 34b as a near-colorless amorphous solid (93 mg,
19%): 1H NMR (DMSO-d6, 500 MHz) δ 9.74 (brs, 1H), 8.43 (s, 1H), 7.71 (s, 1H), 7.15 (d, J
= 1.7 Hz, 1H), 7.07 (dd, J = 8.1, 1.7 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.06 (s, 2H), 6.01 (m,
1H), 5.12-5.07 (m, 2H), 3.46 (d, J = 6.5 Hz, 1H), 2.31 (s, 3H); 13C NMR (DMSO-d6, 125 MHz)
δ 174.8, 157.8, 154.0, 153.5, 147.0, 146.8, 136.4, 126.2, 1225.9, 122.9, 122.7, 122.4, 116.5,
116.2, 111.4, 109.4, 108.1, 101.0, 33.9, 8.8; IR (film) νmax 3205, 2920, 2851, 1634, 1622, 1589,
1574, 1495, 1464, 1435, 1383, 1271, 1240, 1180, 1097, 1070, 1041, 933, 914, 856, 800, 764,
748 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C20H16O5, 337.1076; found, 337.1061.
5.51 8-Allyl-3-(benzo[d][1,3]dioxol-5-yl)-7-hydroxy-4H-chromen-4-one (34c)
The acidic aqueous layers from the construction of 34a were concentrated, water (50 mL) was
added, the precipitate was collected by filtration and washed with cold Et2O to give 8-allyl
34c as a grey amorphous solid (213 mg, 54%): 1H NMR (DMSO-d6, 500 MHz) δ 10.75 (brs,
1H0, 8.42 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.15 (d, J = 1.6 Hz, 1H), 7.07 (dd, J = 8.0, 1.7 Hz,
1H), 7.03 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H), 5.97 (ddt, J = 17.0, 10.2,
6.0 Hz, 1H), 5.02-4.95 (m, 2H), 3.53 (dbrt, J = 6.0, 1.5 Hz, 2H); 13C NMR (DMSO-d6, 125
MHz) δ 174.8, 160.0, 155.3, 153.5, 147.0, 135.3, 125.8, 124.7, 122.8, 116.6, 115.2, 114.3,
112.8, 109.4, 108.1, 101.0, 26.5; IR (film) νmax 3234, 2905, 1618, 1595, 1578, 1483, 1425,
1279, 1250, 1036, 1020 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C19H14O5, 323.0919;
found, 323.0912.
5.52 6-Allyl-3-(benzo[d][1,3]dioxol-5-yl)-4-oxo-4H-chromen-7-yl acetate (35a)
Acetic anhydride (200 μL, 216 mg, 2.12 mmol) was added to 34a (3 mg, 0.01 mmol) in
anhydrous pyridine (200 μL, 196 mg, 2.48 mmol) and the solution was then heated to reflux
for 4 h. After cooling to rt, 1M aqueous HCl solution (5 mL) was added and the solution was
extracted with EtOAc (3 × 10 mL). The organic layers were washed with saturated aqueous
NaHCO3 solution (15 mL), saturated aqueous NaCl solution (20 mL), dried (Na2SO4), filtered,
and concentrated. The residue was purified via column chromatography (SiO2, 4:1
Hexanes:EtOAc) to give 35a as a near-colorless amorphous solid (1.3 mg, 38%): 1H NMR
(CDCl3, 500 MHz) δ 8.19 (s, 1H), 7.96 (s, 1H), 7.28 (s, 1H), 7.10 (d, J = 1.7 Hz, 1H), 6.98
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(dd, J = 8.0, 1.7 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H), 5.93 (ddt, J = 16.9, 10.2, 6.6
Hz, 1H), 5.16-5.07 (m, 2H0, 3.43 (brd, 2H), 2.37 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ
175.9, 168.7, 155.3, 153.1, 153.0, 148.0, 147.9, 135.3, 130.6, 128.1, 125.6, 125.4, 122.6, 122.6,
117.2, 112.1, 109.9, 108.7, 101.4, 34.7, 21.2; IR (film) νmax 3076, 2922, 2854, 1769, 1649,
1618, 1504, 1489, 1439, 1369, 1321, 1246, 1192, 1169, 1105, 1082, 1028, 930, 910, 854, 814
cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C21H16O6, 365.1025; found, 365.1027.
5.53 6-Allyl-3-(benzo[d][1,3]dioxol-5-yl)-8-methyl-4-oxo-4H-chromen-7-yl acetate (35b)
Acetic anhydride (15 μL, 16 mg, 0.16 mmol) was added to 34b (25 mg, 0.07 mmol) in
anhydrous pyridine (110 μL, 108 mg, 1.36 mmol) and the solution was then heated to reflux
for 4 h. After cooling to rt, 1M aqueous HCl solution (5 mL) was added and the solution was
extracted with EtOAc (3 × 10 mL). The organic layers were washed with saturated aqueous
NaHCO3 solution (15 mL), saturated aqueous NaCl solution (20 mL), dried (Na2SO4), filtered,
and concentrated. The residue was purified via column chromatography (SiO2, 4:1
Hexanes:EtOAc) to give 35b as a near-colorless amorphous solid (21 mg, 75%): 1H NMR
(CDCl3, 500 MHz) δ 8.06 (s, 1H), 8.02 (s, 1H), 7.11 (d, J = 1.7 Hz, 1H), 6.99 (dd, J = 8.0, 1.7
Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H), 5.92 (ddt, J = 16.7, 10.3, 6.6 Hz, 1H), 5.15-5.09
(m, 2H), 3.39 (d, J = 6.6 Hz, 2H), 2.39 (s, 3H), 2.29 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ
176.3, 168.4, 154.1, 152.9 (2C), 151.8, 147.9, 135.4, 130.5, 125.7, 125.1, 124.8, 122.6, 122.6,
120.7, 117.2, 109.9, 108.7, 101.4, 35.2, 20.8, 9.7; IR (film) νmax 3078, 2916, 1763, 1645, 1609,
1504, 1491, 1456, 1437, 1371, 1337, 1329, 1279, 1246, 1207, 1183, 1090, 1067, 1040, 924,
899, 954, 812, 729 cm−1; HRMS (ESI+) m/z: [M + Na]+ calcd for C22H18O6, 401.1001; found,
401.1024.
5.54 8-Allyl-3-(benzo[d][1,3]dioxol-5-yl)-4-oxo-4H-chromen-7-yl acetate (35c)
Acetic anhydride (85 μL, 92 mg, 0.90 mmol) was added to 34c (199 mg, 0.62 mmol) in
anhydrous pyridine (630 μL, 616 mg, 7.79 mmol) and the solution was then heated to reflux
for 4 h. After cooling to rt, 1M aqueous HCl solution (5 mL) was added and the solution was
extracted with EtOAc (3 × 10 mL). The organic layers were washed with saturated aqueous
NaHCO3 solution (15 mL), saturated aqueous NaCl solution (20 mL), dried (Na2SO4), filtered,
and concentrated. The residue was purified via column chromatography (SiO2, 4:1:1
Hexanes:CH2Cl2:EtOAc) to give 35c as a near-colorless amorphous solid (205 mg, 92%): 1H
NMR (CDCl3, 500 MHz) δ 8.24 (d, J = 8.8 Hz, 1H), 8.03 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H),
7.11 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 8.0, 1.7 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H),
5.91 (ddt, J = 16.8, 10.3, 6.1 Hz, 1H), 5.10-5.03 (m, 2H), 3.59 (d, J = 6.1 Hz, 2H), 2.38 (s,
3H); 13C NMR (CDCl3, 125 MHz) δ 176.2, 168.9, 155.2, 153.0, 152.8, 148.0, 148.0, 134.3,
125.5, 125.5, 125.2, 122.7, 122.6, 121.6, 120.5, 116.5, 109.9, 108.7, 101.4, 28.2, 21.1; IR (film)
νmax 3078, 3011, 2980, 2901, 1765, 1645, 1618, 1603, 1580, 1504, 1491, 1431, 1369, 1337,
1325, 1279, 1252, 1232, 1180, 1109, 1038, 1022, 924, 895, 851, 812, 771, 733 cm−1; HRMS
(ESI+) m/z: [M + Na]+ calcd for C21H16O6, 387.0845; found, 387.0835.
5.55 3-(Benzo[d][1,3]dioxol-5-yl)-6-(3-methylbut-2-enyl)-4-oxo-4H-chromen-7-yl acetate (36a)
Grubbs’ second generation catalyst (9 mg, 0.01 mmol) was added to 35a (1.4 mg, 3.84 μmol)
in anhydrous CH2Cl2 (300 μL) at rt. After 15 min, 2-methyl-2-butene (1.20 mL) was added
and the reaction was stirred at rt for 18 h. The solvent was concentrated and the residue purified
via PTLC (SiO2, 4:1 Hexanes:EtOAc) to give 36a as a colorless amorphous solid (1.5 mg,
99%): 1H NMR (CDCl3, 500 MHz) δ 8.16 (s, 1H), 7.96 (s, 1H), 7.24 (s, 1H), 7.10 (d, J = 1.7
Hz, 1H), 6.98 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H), 5.25 (t heptet,
J = 7.3, 1.4 Hz, 1H), 3.35 (brd, J = 7.3 Hz, 2H), 2.37 (s, 3H), 1.76 (d, J = 1.4 Hz, 3H), 1.72 (d,
J = 1.4 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 176.0, 168.8, 155.1, 153.1, 152.9 (2C), 147.9,
134.4, 132.2, 127.6, 125.7, 125.3, 122.6, 122.6, 120.9, 111.8, 109.9, 108.6, 101.4, 28.9, 26.0,
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21.2, 18.1; IR (film) νmax 2926, 2854, 1769, 1647, 1618, 1504, 1491, 1474, 1439, 1375, 1246,
1200, 1178, 1105, 1080, 1030, 933, 912, 856, 814, 760, 750 cm−1; HRMS (ESI+) m/z: [M +
H]+ calcd for C23H20O6, 393.1338; found, 393.1332.
5.56 3-(Benzo[d][1,3]dioxol-5-yl)-8-methyl-6-(3-methylbut-2-enyl)-4-oxo-4H-chromen-7-yl
acetate (36b)
Grubbs’ second generation catalyst (3 mg, 3.53 μmol) was added to 35b (21.2 mg, 56.03 μmol)
in anhydrous CH2Cl2 (300 μL) at rt. After 15 min, 2-methyl-2-butene (1.20 mL) was added
and the reaction was stirred at rt for 18 h. The solvent was concentrated and the residue purified
via column chromatography (SiO2, 4:1 Hexanes:EtOAc) to give 36b as a colorless amorphous
solid (13 mg, 57%): 1H NMR (CDCl3, 500 MHz) δ 8.03 (brs, 1H), 8.02 (s, 1H), 7.11 (d, J =
1.7 Hz, 1H), 6.99 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.00 (s, 2H), 5.25 (t heptet,
J = 7.2, 1.4 Hz, 1H), 3.31 (brd, J = 7.2 Hz, 2H), 2.40 (s, 3H), 2.29 (s, 3H), 1.76 (d, J = 1.4 Hz,
3H), 1.71 (d, J = 1.4 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 176.4, 168.4, 153.8, 152.8, 151.8,
147.9, 147.9, 134.2, 132.0, 125.8, 125.0, 124.3, 122.6, 122.5, 121.0, 120.4, 109.9, 108.6, 101.4,
29.3, 26.0, 20.7, 18.1, 9.7; IR (film) νmax 3342, 3074, 2974, 2926, 2918, 1763, 1645, 1607,
1504, 1491, 1454, 1441, 1371, 1337, 1275, 1246, 1209, 1183, 1090, 1068, 1040, 933, 899,
858, 812, 737 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C24H22O6, 407.1495; found,
407.1516.
5.57 3-(Benzo[d][1,3]dioxol-5-yl)-8-(3-methylbut-2-enyl)-4-oxo-4H-chromen-7-yl acetate (36c)
Grubbs’ second generation catalyst (26 mg, 0.03 mmol) was added to 35c (153.7 mg, 0.42
mmol) in anhydrous CH2Cl2 (5.00 mL) at rt. After 15 min, 2-methyl-2-butene (10.5 mL) was
added and the reaction was stirred at rt for 18 h. The solvent was concentrated and the residue
purified via column chromatography (SiO2, 4:1:1 Hexanes:CH2Cl2:EtOAc) to give 36c as a
colorless amorphous solid (98 mg, 88%): 1H NMR (CDCl3, 500 MHz) δ 8.20 (d, J = 8.8 Hz,
1H), 8.03 (s, 1H), 7.15 (d, J = 8.8 Hz, 1H), 7.12 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 8.0, 1.7 Hz,
1H), 6.89 (d, J = 8.0 Hz, 1H), 6.01 (s, 2H), 5.16 (t heptet, J = 7.1, 1.4 Hz, 1H), 3.52 (brd, J =
7.1 Hz, 2H), 2.38 (s, 3H), 1.82 (d, J = 1.4 Hz, 3H), 1.71 (d, J = 1.4 Hz, 3H); 13C NMR
(CDCl3, 125 MHz) δ 176.2, 169.0, 155.3, 152.8, 152.6, 148.0, 148.0, 133.5, 125.6, 125.2,
125.0, 123.5, 122.8, 122.6, 120.5, 120.5, 109.9, 108.7, 101.4, 25.9, 23.3, 21.1, 18.1; IR (film)
νmax 3067, 2980, 2912, 1765, 1645, 1618, 1603, 1578, 1504, 1489, 1429, 1369, 1327, 1279,
1252, 1232, 1202, 1180, 1107, 1034, 935, 922, 901, 864, 852, 814, 770 cm−1; HRMS (ESI+)
m/z: [M + H]+ calcd for C23H20O6, 393.1338; found, 393.1333.
5.58 3-(Benzo[d][1,3]dioxol-5-yl)-7-hydroxy-6-(3-methylbut-2-enyl)-4H-chromen-4-one (37a)
Potassium carbonate (5 mg, 36 μmol) was added to 36a (1.5 mg, 38 μmol) in MeOH (2.0 mL)
and the solution was stirred at rt. After 18 h, the pH was adjusted to 3 with 6M aqueous HCl
solution and the solvent was concentrated. The residue was extracted with 1:1 CH2Cl2:MeOH
(3 × 5 mL) and the organic layers were concentrated. The residue was purified via PTLC
(SiO2, 4:1:1 Hexanes:CH2Cl2:EtOAc) to give 37a as a colorless amorphous solid (0.9 mg,
67%): 1H NMR (CDCl3, 500 MHz) δ 8.04 (s, 1H), 7.89 (s, 1H), 7.10 (d, J = 1.7 Hz, 1H), 6.98
(dd, J = 8.0, 1.7 Hz, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.85 (s, 1H), 6.08 (brs, 1H), 6.00 (s, 2H0,
5.34 (t heptet, J = 7.2, 1.4 Hz, 1H), 3.48 (brd, J = 7.2 Hz, 2H), 1.82-1.80 (m, 6H); 13C NMR
(CDCl3, 125 MHz) δ 176.0, 159.8, 156.7, 152.4, 147.9, 147.8, 136.6, 127.4, 126.5, 126.0,
125.0, 122.6, 120.9, 118.5, 110.0, 108.6, 103.4, 101.4, 29.9, 26.1, 18.2; IR (film) νmax 3194,
2957, 2922, 2853, 1616, 1583, 1504, 1487, 1464, 1435, 1385, 1333, 1273, 1254, 1207, 1140,
1105, 1036, 933, 856, 814, 748 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C21H18NO5,
351.1233; found, 351.1216.
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Potassium carbonate (41 mg, 0.30 mmol) was added to 36b (13 mg, 32 μmol) in MeOH (1.0
mL) and the solution was stirred at rt. After 1 h, the reaction was diluted with 1M aqueous HCl
solution (10 mL) and was extracted with CH2Cl2 (3 × 20 mL). The organic layers were washed
with saturated aqueous NaCl solution (50 mL), dried (Na2SO4), filtered, and concentrated. The
residue was purified via column chromatography (SiO2, 8:1:1 Hexanes:CH2Cl2:EtOAc) then
PTLC (SiO2, 4:1:1 Hexanes:CH2Cl2:EtOAc) to give 37b as a colorless amorphous solid (1.8
mg, 15%): 1H NMR (CDCl3, 500 MHz) δ 7.98 (s, 1H), 7.93 (brs, 1H), 7.12 (d, J = 1.7 Hz,
1H), 6.99 (dd, J = 8.0, 1.7 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.00 (s, 2H), 5.98 (brs, 1H), 5.33
(t heptet, J = 7.3, 1.4 Hz, 1H), 3.49 (brd, J = 7.3 Hz, 2H), 2.34 (s, 3H), 1.85 (d, J = 1.4 Hz,
3H), 1.82 (d, J = 1.4 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 176.5, 157.6, 155.0, 152.5, 147.8,
147.7, 137.1, 126.2, 125.2, 124.6, 124.2, 122.6, 121.1, 118.2, 112.2, 110.0, 108.6, 101.3, 20.7,
29.9, 26.1, 18.2, 8.3; IR (film) νmax 3292, 2957, 2922, 2854, 1717, 1622, 1591, 1580, 1504,
1491, 1464, 1437, 1377, 1337, 1327, 1281, 1238, 1186, 1148, 1095, 1070, 1040, 937, 856,
812, 735 cm−1; HRMS (ESI+) m/z: [M + H]+ calcd for C22H20O5, 365.1389; found, 365.1382.
5.60 3-(Benzo[d][1,3]dioxol-5-yl)-7-hydroxy-8-(3-methylbut-2-enyl)-4H-chromen-4-one (37c)
Potassium carbonate (83 mg, 0.60 mmol) was added to 36c (47 mg, 0.12 mmol) in MeOH (1.60
mL) and the solution was stirred at rt. After 1 h, the reaction was diluted with 1M aqueous HCl
solution (10 mL) and was extracted with CH2Cl2 (3 × 20 mL). The organic layers were washed
with saturated aqueous NaCl solution (50 mL), dried (Na2SO4), filtered, and concentrated.
Cold Et2O (10 mL) was added to the residue and the precipitate was collected by filtration to
give 37c as a colorless amorphous solid (18 mg, 43%): 1H NMR (CDCl3, 500 MHz) δ 8.10
(d, J = 8.8 Hz, 1H), 7.98 (s, 1H), 7.11 (d, J = 1.7 Hz, 1H), 6.99 (dd, J = 8.0, 1.7 Hz, 1H), 6.92
(d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.04 (s, 1H), 6.00 (s, 2H), 5.29 (t heptet, J = 7.2,
1.4 Hz, 1H), 3.63 (brd, J = 7.2 Hz, 2H), 1.88 (d, J = 1.4 Hz, 3H), 1.79 (d, J = 1.4 Hz,
3H); 13C NMR (CDCl3, 125 MHz) δ 176.4, 159.1, 155.5, 152.4, 147.9, 147.8, 136.1, 125.9,
125.7, 124.7, 122.6, 120.6, 118.7, 115.0, 114.5, 110.0, 108.6, 101.4, 26.0, 22.4, 18.2; IR (film)
νmax 3221, 2899, 1620, 1595, 1576, 1502, 1489, 1427, 1379, 1335, 1310, 1279, 1248, 1177,
1159, 1107, 1034, 856, 810 cm−1; HRMS (ESI+) m/z: [M + Na]+ calcd for C21H18O5, 373.1052;
found, 373.1033.
5.61 Anti-Proliferation Assays
Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with
non-essential amino acids, L-glutamine (2 mM), streptomycin (500 μg/mL), penicillin (100
units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C,
5% CO2), seeded (2000/well, 100 μL) in 96-well plates, and allowed to attaché overnight.
Compound or GDA at varying concentrations in DMSO (1% DMSO final concentration) was
added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells
was determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer’s
instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were
adjusted accordingly. IC50 values were calculated from separate experiments performed in
triplicate using GraphPad Prism.
5.62 Western Blot Analyses
MCF-7 cells were cultured as described above and treated with various concentrations of drug,
GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were
harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium
orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10
min at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit
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per the manufacturer’s instructions. Equal amounts of protein (20 μg) were electrophoresed
under reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with
the corresponding specific antibodies. Membranes were incubated with an appropriate
horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent
substrate, and visualized.
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Structures of novobiocin, A4, and A4-dimer.
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Proposed overlay of novobiocin analogues (eg. 3) and 2 that were used to prepare flavone and
isoflavone chimeras (4).
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Western blot analysis of Hsp90 and Hsp90 client proteins against MCF-7 breast cancer cells.
Concentrations (in μM) of 26b (top) and 37c (bottom) are indicated above each lane. GDA
(geldanamycin, 500 nM) and DMSO were respectively employed as positive and negative
controls.
Mays et al. Page 33














Summary of structure–activity trends for chimeric analogues of novobiocin and derrubone.
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Representative retrosynthesis of isoflavone chimeric analogues.
Mays et al. Page 35














Preparation of 2-amido-flavone analogues.
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Preparation of 3-amido-isoflavone analogues.
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Preparation of (3,4-methylenedioxy)phenyl-isoflavone analogues.
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Preparation of 5-deoxy-derrubone analogues.
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Table 1
Antiproliferation activities of 2-amido-flavone analogues
Entry (IC50, μM) R3 R5 MCF-7 SkBr3
16a CH3 H > 100a > 100
16b biaryl H 10.5 ± 0.1 19.6 ± 2.9
17a CH3 Ac > 100 > 100
17b biaryl Ac > 100 > 100
18a CH3 noviose > 100 > 100
18b biaryl noviose 14.7 ± 3.0 33.8 ± 0.7
a
Values represent mean ± standard deviation for at least two separate experiments performed in triplicate.
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